documents incorporated reference portions abbvie inc proxy statement incorporated reference part iii definitive proxy statement filed march abbvie inc year ended december table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures information executive officers part ii item market registrants common equity related stockholder matters issuer purchases equity securities item reserved item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accounting fees services part iv item exhibits financial statement schedules item summary signatures part item business overview abbvie global researchbased biopharmaceutical company abbvie uses expertise dedicated people unique approach innovation develop market advanced therapies address worlds complex serious diseases may abbvie completed acquisition allergan plc allergan acquisition allergan creates diversified biopharmaceutical company positioned success comprehensive product portfolio leadership positions key therapeutic areas immunology hematologic oncology aesthetics neuroscience eye care women 's health abbvie 's existing product portfolio pipeline enhanced numerous allergan assets allergan 's product portfolio benefits abbvie 's commercial strength expertise international infrastructure see note licensing acquisitions arrangementsacquisition allergan consolidated financial statements included item financial statements supplementary data subsequent acquisition date abbvie 's consolidated financial statements include assets liabilities operating results cash flows allergan abbvie incorporated delaware april january abbvie became independent publiclytraded company result distribution abbott laboratories abbott outstanding common stock abbvie abbott 's shareholders impact coronavirus disease covid novel coronavirus covid pandemic continues spread throughout united states around world response growing public health crisis abbvie partnered global authorities support experimental use multiple abbvie assets determine efficacy treatment covid abbvie continues closely manage manufacturing supply chain resources around world help ensure patients continue receive uninterrupted supply medicines clinical trial sites monitored locally protect safety study participants staff employees impact covid abbvie 's operations date material abbvie experienced lower new patient starts across therapeutic portfolio abbvie expects matter could continue negatively impact results operations throughout duration outbreak extent covid may impact abbvie 's financial condition results operations remains uncertain segments abbvie operates single global business segment dedicated research development manufacturing commercialization sale innovative medicines therapies operating structure enables chief executive officer chief operating decision maker codm allocate resources assess business performance global basis order achieve established longterm strategic goals consistent structure global research development supply chain organization responsible discovery development manufacturing supply products commercial efforts coordinate marketing sales distribution products organized geographic region therapeutic area activities supported global corporate administrative staff determination single business segment consistent consolidated financial information regularly reviewed codm purposes assessing performance allocating resources planning forecasting future periods see note segment geographic area information consolidated financial statements included item financial statements supplementary data sales information related abbvie 's key products geographies included item management 's discussion analysis financial condition results operations used throughout text report terms abbvie company refer abbvie inc delaware corporation abbvie inc consolidated subsidiaries context requires form kproducts abbvie 's portfolio products includes broad line therapies address world 's complex serious diseases immunology products abbvie maintains extensive immunology portfolio across rheumatology dermatology gastroenterology abbvie 's immunology products address unmet needs patients autoimmune diseases products humira humira adalimumab biologic therapy administered subcutaneous injection approved treat following autoimmune diseases united states canada mexico collectively north america european union condition principal markets rheumatoid arthritis moderate severe north america european union psoriatic arthritis north america european union ankylosing spondylitis north america european union adult crohn 's disease moderate severe north america european union plaque psoriasis moderate severe chronic north america european union juvenile idiopathic arthritis moderate severe polyarticular north america european union ulcerative colitis moderate severe north america european union axial spondyloarthropathy european union pediatric crohn 's disease moderate severe north america european union hidradenitis suppurativa moderate severe north america european union pediatric enthesitisrelated arthritis european union noninfectious intermediate posterior panuveitis north america european union pediatric ulcerative colitis moderate severe european union pediatric uveitis european union humira also approved japan treatment intestinal behet 's disease pyoderma gangrenosum humira sold numerous markets worldwide including japan china brazil australia accounted approximately abbvie 's total net revenues skyrizi skyrizi risankizumab interleukin il inhibitor selectively blocks il binding p subunit biologic therapy administered quarterly subcutaneous injection following induction dose skyrizi approved united states canada european union indicated treatment moderate severe plaque psoriasis adults candidates systemic therapy phototherapy japan skyrizi approved treatment plaque psoriasis generalized pustular psoriasis erythrodermic psoriasis psoriatic arthritis adult patients inadequate response conventional therapies rinvoq rinvoq upadacitinib oral oncedaily selective reversible jak inhibitor approved united states canada japan european union rinvoq indicated treatment moderate severe active rheumatoid arthritis adult patients responded inadequately intolerant one diseasemodifying antirheumatic drugs dmards rinvoq also approved european union treatment adult patients active psoriatic arthritis adult patients active ankylosing spondylitis rinvoq may used monotherapy combination methotrexate rinvoq also indicated japan patients rheumatoid arthritis inadequate response conventional therapy including inhibition progression structural damage oncology products abbvies oncology products target complex difficulttotreat cancers products imbruvica imbruvica ibrutinib oral oncedaily therapy inhibits protein called bruton 's tyrosine kinase btk imbruvica one first medicines receive united states food drug administration fda approval granted breakthrough therapy designation one therapies receive four separate designations imbruvica currently approved treatment adult patients chronic lymphocytic leukemia cllsmall lymphocytic lymphoma sll cllsll p deletion mantle cell lymphoma mcl received least one prior therapy waldenstrms macroglobulinemia wm marginal zone lymphoma mzl require systemic therapy received least one prior anticdbased therapy chronic graft versus host disease cgvhd failure one lines systemic therapy accelerated approval granted indication based overall response rate continued approval indication may contingent upon verification clinical benefit confirmatory trials venclextavenclyxto venclexta venetoclax bcl inhibitor used treat hematological malignancies venclexta approved fda adults cll sll addition venclexta approved combination azacitidine decitabine lowdose cytarabine treat adults newly diagnosed acute myeloid leukemia aml years age older medical conditions prevent use standard chemotherapy venclyxto approved europe cll combination obinutuzumab patients previously untreated cll combination rituximab patients received least one previous treatment aesthetics products abbvies allergan aesthetics portfolio consists toxins dermal fillers plastics regenerative medicine body contouring skincare products hold marketleading positions us key markets around world us sales comprised approximately two thirds total global sales products botox cosmetic botox cosmetic acetylcholine release inhibitor neuromuscular blocking agent indicated temporary improvement appearance moderate severe glabellar lines frown lines eyebrows moderate severe crow 's feet forehead lines adults received initial us food drug administration fda approval botox cosmetic approved use major markets around world become one worlds recognized iconic brands juvederm collection juvederm collection portfolio hyaluronic acidbased dermal fillers variety approved indications us major markets around world treat volume loss cheeks chin lips lower face aesthetics aesthetics products include limited coolsculpting body contouring technology alloderm regenerative dermal tissue natrelle breast implants skinmedica skincare line diamondglow neuroscience products abbvies neuroscience products address difficulttotreat neurologic diseases products botox therapeutic botox therapeutic onabotulinumtoxina injection neuromuscular blocking agent injected muscle tissue treatment following indications united states treatment overactive bladder symptoms urge urinary incontinence urgency frequency adults inadequate response intolerant anticholinergic medication treatment urinary incontinence due detrusor overactivity associated neurologic condition eg spinal cord injury multiple sclerosis adults inadequate response intolerant anticholinergic medication prophylaxis headaches adult patients chronic migraine days per month headache lasting hours day longer treatment spasticity patients years age older treatment adults cervical dystonia reduce severity abnormal head position neck pain associated cervical dystonia treatment strabismus blepharospasm associated dystonia including benign essential blepharospasm vii nerve disorders patients years age older treatment severe primary axillary hyperhidrosis inadequately managed topical agents licenses around world vary focal spasticity associated dynamic equinus foot deformity due spasticity ambulant pediatric cerebral palsy patients two years age older focal spasticity wrist hand adult post stroke patients focal spasticity ankle foot adult post stroke patients vraylar vraylar cariprazine dopamine dpreferring dd receptor partial agonist hta receptor partial agonist binding profile may linked observed improvements negative symptoms schizophrenia antidepressant effects bipolar disorder vraylar indicated acute maintenance treatment schizophrenia adults acute treatment manic mixed episodes associated bipolar disorder adults acute treatment depressive episodes associated bipolar disorder bipolar depression adults duopa duodopa carbidopa levodopa abbvie 's levodopacarbidopa intestinal gel treatment advanced parkinson 's disease marketed duopa united states duodopa outside united states ubrelvy ubrelvy ubrogepant indicated acute treatment migraine without aura adults commercialized united states eye care products abbvies eye care products address unmet needs new approaches help preserve protect patients vision products lumiganganfort lumigan bimatoprost ophthalmic solution daily topical prostaglandin analog indicated reduction elevated intraocular pressure iop patients open angle glaucoma oag ocular hypertension oht ganfort daily topical fixed combination bimatoprost timolol reduction iop adult patients oag oht lumigan sold united states numerous markets around world ganfort approved eu markets south america middle east asia alphagancombigan alphagan brimonidine tartrate ophthalmic solution alphaadrenergic receptor agonist indicated reduction elevated intraocular pressure iop patients openangle glaucoma ocular hypertension combigan brimonidine tartratetimolol maleate ophthalmic solution approved reducing elevated intraocular pressure iop patients glaucoma require additional adjunctive iop lowering therapy alphagan combigan available sale united states numerous markets around world restasis restasis calcineurin inhibitor immunosuppressant indicated increase tear production patients whose tear production presumed suppressed due ocular inflammation associated keratoconjunctivitis sicca restasis approved united states number markets south america middle east asia eye care eye care products include xen durysta ozurdex refreshoptive women 's health products abbvies women 's health products lo loestrin lo loestrin fe oral contraceptive indicated prevention pregnancy lowest dose estrogen mcg dispensed unique regimen twoday hormonefree interval marketed us lo loestrin fe norethindrone acetate ethinyl estradiol tablets ethinyl estradiol tablets ferrous fumarate tablets select markets outside us lolo orilissaoriahnn orilissa elagolix first orallyadministered nonpeptide small molecule gonadotropinreleasing hormone gnrh antagonist specifically developed women moderate severe endometriosis pain fda approved orilissa priority review represents first fdaapproved oral treatment management moderate severe pain associated endometriosis decade orilissa inhibits endogenous gnrh signaling binding competitively gnrh receptors pituitary gland administration results dosedependent suppression luteinizing hormone folliclestimulating hormone leading decreased blood concentrations ovarian sex hormones estradiol progesterone outside united states orilissa also launched canada puerto rico oriahnn elagolix estradiol norethindrone acetate capsules elagolix capsules combination prescription medicine used control heavy menstrual bleeding related uterine fibroids women menopause women 's health women 's health includes liletta sterile levonorgestrelreleasing intrauterine system indicated prevention pregnancy six years hormonal ius intrauterine system approved us six years pregnancy prevention key products abbvies key products include among things treatments patients hepatitis c virus hcv metabolic hormone products target number conditions including exocrine pancreatic insufficiency hypothyroidism well endocrinology products palliative treatment advanced prostate cancer treatment endometriosis central precocious puberty preoperative treatment patients anemia caused uterine fibroids products mavyretmaviret mavyret glecaprevirpibrentasvir approved united states european union maviret treatment adult pediatric patients years older weighing least kilograms chronic hcv genotype infection without cirrhosis compensated cirrhosis childpugh also indicated treatment adult pediatric patients years older weighing least kilograms hcv genotype infection previously treated regimen containing hcv nsa inhibitor nsa protease inhibitor week pangenotypic treatment patients without cirrhosis following expedition study also patients compensated cirrhosis new treatment creon creon pancrelipase pancreatic enzyme therapy exocrine pancreatic insufficiency condition occurs patients cystic fibrosis chronic pancreatitis several conditions lupron lupron leuprolide acetate also marketed lucrin lupron depot product palliative treatment advanced prostate cancer treatment endometriosis central precocious puberty preoperative treatment patients anemia caused uterine fibroids lupron approved daily subcutaneous injection onemonth threemonth fourmonth sixmonth intramuscular injection linzessconstella linzess linaclotide oncedaily guanylate cyclasec agonist used adults treat irritable bowel syndrome constipation ibsc chronic idiopathic constipation cic product marketed linzess united states constella outside united states synthroid synthroid levothyroxine sodium tablets usp used treatment hypothyroidism abbvie rights sell creon synthroid united states abbvie 's commercial rights sale distribution synagis outside united states revert astrazeneca upon expiry current agreement marketing sales distribution capabilities abbvie utilizes combination dedicated commercial resources regional commercial resources distributorships market sell distribute products worldwide abbvie directs primary marketing efforts toward securing prescription recommendation brand products physicians key opinion leaders health care providers managed care providers example health maintenance organizations pharmacy benefit managers hospitals state federal government agencies example united states department veterans affairs united states department defense also important customers abbvie also markets directly consumers although united states many company 's products must sold pursuant prescription outside united states abbvie focuses promotional market access efforts key opinion leaders payers physicians health systems abbvie also provides patient support programs closely related products throughout covid pandemic abbvie maintained promotional activities key stakeholders leveraging digital engagement permitted compliance locally applicable government guidance abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses certain products including aesthetic products devices also sold directly physicians licensed healthcare providers although abbvie 's business significant seasonality abbvie 's product revenues may affected end customer retail buying patterns fluctuations wholesaler inventory levels factors form kin united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly retailers pharmacies patients three wholesale distributors mckesson corporation cardinal health inc amerisourcebergen corporation accounted substantially abbvie 's sales united states individual wholesaler accounted greater abbvie 's gross revenues united states outside united states abbvie sells products primarily customers distributors depending market served certain products comarketed copromoted companies abbvie single customer customer lost would material adverse effect company 's business material portion abbvie 's business subject renegotiation profits termination contracts election government orders generally filled current basis order backlog material abbvie 's business competition markets abbvie 's products highly competitive abbvie competes researchbased pharmaceuticals biotechnology companies discover manufacture market sell proprietary pharmaceutical products therapies biologics example humira competes antitnf products competitive products intended treat number disease states mavyretmaviret competes available hcv treatment options addition past years number companies started develop successfully developed andor currently marketing products positioned competitors botox search technological innovations pharmaceutical products significant aspect competition introduction new products competitors changes medical practices procedures result product obsolescence price also competitive factor addition substitution generic pharmaceutical products branded pharmaceutical products creates competitive pressures abbvie 's products patent protection new products treatments brought market abbvies competitors could cause revenues abbvies products decrease due price reductions sales volume decreases biosimilars competition abbvies biologic products affected approval followon biologics also known biosimilars biologics added major therapeutic options treatment many diseases including therapies unavailable inadequate cost developing producing biologic therapies typically dramatically higher conventional small molecule medications many biologic medications used ongoing treatment chronic diseases rheumatoid arthritis inflammatory bowel disease treatment previously untreatable cancer significant investments biologics infrastructure manufacturing necessary produce biologic products humira facing direct biosimilar competition europe countries abbvie continue face competitive pressure biologics orally administered products united states fda regulates biologics federal food drug cosmetic act ffdca public health service act phsa regulations implementing acts enactment federal health care reform legislation march provided pathway approval biosimilars phsa approval process science behind biosimilars complex approval fda dependent upon many factors including showing biosimilar highly similar original product clinically meaningful differences original product terms safety purity potency types data could ordinarily required application show similarity may include analytical data bioequivalence studies studies demonstrate chemical similarity animal studies including toxicity studies clinical studies furthermore law provides biosimilar product determined interchangeable considered fda substitutable original biologic product without intervention health care provider prescribed original biologic product prove biosimilar product interchangeable applicant must demonstrate product expected produce clinical results original biologic product given patient product administered patient safety risks potential diminished efficacy alternating switching use interchangeable biosimilar biologic product original biologic product greater risk using original biologic product without switching law continues interpreted implemented fda result ultimate impact implementation meaning remains subject uncertainty intellectual property protection regulatory exclusivity generally upon approval products may entitled certain kinds exclusivity applicable intellectual property regulatory regimes abbvies intellectual property materially valuable company abbvie seeks patent protection available significant markets andor countries product development united states expiration date patents years filing date given patents relating pharmaceutical products often obtained early development process given amount time needed complete clinical trials development activities required regulatory approval length time product launch patent expiration significantly less years drug price competition patent term restoration act commonly known hatchwaxman act permits patent holder seek patent extension commonly called patent term restoration patents products processes making product regulated ffdca length patent extension roughly based percent period time filing investigational new drug application nda compound submission nda compound plus percent time period nda submission regulatory approval extension however exceed five years patent term remaining regulatory approval exceed years biological products licensed phsa similarly eligible terms patent restoration pharmaceutical products may entitled forms legal regulatory exclusivity upon approval scope length requirements exclusivities vary united states jurisdictions united states fda approves drug product contains active ingredient previously approved product typically entitled five years nonpatent regulatory exclusivity products may entitled three years exclusivity approval based fdas reliance new clinical studies essential approval submitted nda applicant nda applicant studies product use children fda may grant pediatric exclusivity extends days existing exclusivities patent regulatory related product products either used treat conditions afflict relatively small population reasonable expectation research development costs recovered fda may designate pharmaceutical orphan drug grant seven years market exclusivity types regulatory exclusivity may also available generating new antibiotic incentives gain exclusivity provide new antibiotic new antifungal drugs additional years marketing exclusivity added certain exclusivities already provided law applicable laws regulations dictate scope exclusivity product particular characteristics product entitled upon approval particular country certain instances regulatory exclusivity may offer protection patent protection longer available period time excess patent protection possible estimate product development total period scope exclusivity may become entitled regulatory approval obtained sometimes even later however given length time required complete clinical development pharmaceutical product periods exclusivity might achieved individual case would expected exceed minimum three years maximum years estimates consider factors difficulty recreating manufacturing process particular product proprietary knowledge may delay introduction generic followon product expiration applicable patent regulatory exclusivity periods biologics may entitled exclusivity biologics price competition innovation act passed march title vii patient protection affordable care act law provides pathway approval biosimilars following expiration years regulatory exclusivity innovator biologic potential additional dayextension term conducting pediatric studies biologics also eligible orphan drug exclusivity discussed law also includes extensive process innovator biologic biosimilar manufacturer litigate patent infringement validity enforceability european union also created pathway approval biosimilars published guidelines approval certain biosimilar products complex nature biologics biosimilar products led close regulatory scrutiny followon biosimilar products reduce effect biosimilars sales innovator biologic compared sales erosion caused generic versions small molecule pharmaceutical products abbvie owns licensed rights substantial number patents patent applications abbvie licenses owns patent portfolio thousands patent families includes united states patent applications andor issued patents may also contain nonunited states counterparts patents applications patents applications including various patents expire period late aggregate believed material importance operation abbvies business however abbvie believes single patent license trademark related group patents licenses trademarks except related adalimumab sold trademark humira material relation companys business whole united states composition matter compound patent covering adalimumab expired december equivalent european union patent expired october majority european union countries united states noncomposition matter patents covering adalimumab expire earlier abbvie entered settlement license agreements several adalimumab biosimilar manufactures agreements license united states begin license europe began form kin addition following patents licenses trademarks significant related ibrutinib sold trademark imbruvica related risankizumab sold trademark skyrizi united states composition matter patent covering ibrutinib expected expire united states composition matter patent covering risankizumab expected expire abbvie may rely circumstances trade secrets protect technology abbvie seeks protect technology product candidates part confidentiality agreements employees consultants advisors contractors collaborators agreements may breached abbvie may adequate remedies breach addition abbvies trade secrets may otherwise become known independently discovered competitors extent abbvies employees consultants advisors contractors collaborators use intellectual property owned others work company disputes may arise rights related resulting knowhow inventions licensing acquisitions arrangements addition independent efforts develop market products abbvie enters arrangements acquisitions optiontoacquire agreements licensing arrangements optiontolicense arrangements strategic alliances copromotion arrangements codevelopment comarketing agreements joint ventures acquisitions optiontoacquire agreements typically include among terms conditions nonrefundable purchase price payments option fees option exercise payments milestones earnouts customary terms obligations licensing arrangements typically include among terms conditions nonrefundable upfront license fees option fees option exercise payments milestone payments royalty andor profit sharing obligations see note licensing acquisitions arrangementsother licensing acquisitions activity consolidated financial statements included item financial statements supplementary data third party agreements abbvie agreements third parties process development product distribution analytical services manufacturing certain products abbvie procures certain products services limited number suppliers cases single supply source addition abbvie agreements third parties active pharmaceutical ingredient product manufacturing formulation development services fill finish packaging services transportation distribution logistics services certain products abbvie believe manufacturing related agreements material abbvie 's business substantially dependent individual agreement cases abbvie maintains alternate supply relationships utilize without undue disruption manufacturing processes third party fails perform contractual obligations abbvie also maintains sufficient inventory product minimize impact supply disruption abbvie also party certain collaborations arrangements discussed note licensing acquisitions arrangementsother licensing acquisitions activity consolidated financial statements included item financial statements supplementary data sources availability raw materials abbvie purchases ordinary course business raw materials supplies essential operations numerous suppliers around world addition certain medical devices components necessary manufacture abbvie products provided unaffiliated third party suppliers lupron nearterm supply issue impacted availability certain formulations abbvie experienced recent significant availability problems supply shortages impacted fulfillment product demand research development activities abbvie makes significant investment research development numerous compounds clinical development including potential treatments complex lifethreatening diseases abbvie 's ability discover develop new compounds enhanced company 's use integrated discovery development project teams include chemists biologists physicians pharmacologists work compounds team abbvie also partners third parties biotechnology companies pharmaceutical companies academic institutions identify prioritize promising new treatments complement enhance abbvies existing portfolio abbvie also supplements research development efforts acquisitions research development process generally begins discovery research focuses identification molecule desired effect given disease preclinical testing identified compound proves successful compound moves clinical development generally includes following phases phase involves first human tests small number healthy volunteers patients assess safety tolerability potential dosing phase tests drug 's efficacy disease relatively small group patients phase tests drug demonstrates favorable results earlier phases significantly larger patient population demonstrate efficacy safety based regulatory criteria clinical trials development phases provide data required prepare submit nda biological license application bla submission regulatory approval fda similar government agencies outside united states specific requirements eg scope clinical trials obtaining regulatory approval vary across different countries geographic regions research development process discovery new drug launch typically takes years even longer research development new pharmaceutical products significant amount inherent uncertainty guarantee molecule receive regulatory approval required launch new drug indication addition development new products new formulations research development projects also may include phase trials sometimes called postmarketing studies projects clinical trials designed conducted collect additional data regarding among parameters benefits risks approved drug regulationdiscovery clinical development united states securing approval market new pharmaceutical product united states requires substantial effort financial resources takes several years complete applicant must complete preclinical tests submit protocols fda commencing clinical trials clinical trials intended establish safety efficacy pharmaceutical product typically conducted sequential phases although phases may overlap combined required clinical testing successful results submitted fda form nda bla requesting approval market product one indications fda reviews nda bla determine whether product safe effective intended use whether manufacturing compliant current good manufacturing practices cgmp even nda bla receives approval applicant must comply postapproval requirements example holders approval must report adverse reactions provide updated safety efficacy information comply requirements concerning advertising promotional materials activities also quality control manufacturing procedures must continue conform cgmp approval certain changes manufacturing procedures finished product must submitted approved fda prior implementation fda periodically inspects manufacturing facilities assess compliance cgmp imposes extensive procedural record keeping requirements addition condition approval fda may require postmarketing testing surveillance assess monitor product 's safety efficacy commercialization may require additional clinical trials patient registries observational data additional work chemistry manufacturing controls postapproval regulatory obligations cost complying obligations could expand future fda continues regulate product labeling prohibits promotion products unapproved offlabel uses along labeling restrictions form koutside united states abbvie subject similar regulatory requirements outside united states approval marketing pharmaceutical products abbvie must obtain approval clinical trial application product applicable supervising regulatory authorities commence clinical trials marketing product target markets approval requirements process country vary time required obtain approval may longer shorter required fda approval united states example abbvie may submit marketing authorizations european union either centralized decentralized procedure centralized procedure mandatory approval biotechnology products many pharmaceutical products provides single marketing authorization valid european union member states centralized procedure single marketing authorization application submitted european medicines agency ema agency evaluates application makes recommendation european commission makes final determination whether approve application decentralized procedure provides mutual recognition individual national approval decisions available products subject centralized procedure japan applications approval new product made pharmaceutical medical devices agency pmda japanspecific trials andor bridging studies demonstrate nonjapanese clinical data applies japanese patients may required completing comprehensive review pmda reports ministry health labour welfare approves denies application similarly applications new product china submitted center drug evaluation cde national medical products administration nmpa technical review approval product marketing china clinical data chinese subjects required support approval china requiring inclusion china global pivotal studies separate chinaasian clinical trial regulatory process many emerging markets continues evolve many emerging markets including asia generally require regulatory approval obtained large developed market united states europe country begin complete regulatory review process similar requirements japan china certain countries notably south korea taiwan russia also require local clinical studies conducted order support regulatory approval country requirements governing conduct clinical trials product licensing also vary addition postapproval regulatory obligations adverse event reporting cgmp compliance generally apply may vary country example marketing authorization granted european union periodic safety reports must submitted pharmacovigilance measures may required risk management plans regulationcommercialization distribution manufacturing manufacture marketing sale promotion distribution abbvie 's products subject comprehensive government regulation government regulation various national regional federal state local agencies united states countries addresses among matters inspection controls research laboratory procedures clinical investigations product approvals manufacturing labeling packaging marketing promotion pricing reimbursement sampling distribution quality control postmarketing surveillance record keeping storage disposal practices abbvie 's operations also affected trade regulations many countries limit import raw materials finished products laws regulations seek prevent corruption bribery marketplace including united states foreign corrupt practices act united kingdom bribery act provide guidance corporate interactions government officials require safeguards protection personal data addition abbvie subject laws regulations pertaining health care fraud abuse including state federal antikickback false claims laws united states prescription drug manufacturers abbvie also subject taxes well application product user fees compliance laws regulations costly materially affects abbvie 's business among effects health care regulations substantially increase time difficulty costs incurred obtaining maintaining approval market newly developed existing products abbvie expects compliance regulations continue require significant technical expertise capital investment ensure compliance failure comply delay release new product result regulatory enforcement actions seizure recall product suspension revocation authority necessary product 's production sale civil criminal sanctions including fines penalties addition regulatory initiatives abbvie 's business affected ongoing studies utilization safety efficacy outcomes health care products components regularly conducted industry participants government agencies others studies lead updates data regarding utilization safety efficacy previously marketed products cases studies resulted may future result discontinuance limitations marketing products domestically worldwide may give rise claims damages persons believe injured result use access human health care products continues subject oversight investigation action governmental agencies legislative bodies private organizations united states countries major focus cost containment efforts reduce health care costs also made private sector notably health care payers providers instituted various cost reduction containment measures abbvie expects insurers providers continue attempts reduce cost health care products outside united states many countries control price health care products directly indirectly reimbursement payment pricing coverage limitations compulsory licensing political budgetary pressures united states countries may also heighten scope severity pricing pressures abbvie 's products foreseeable future united states specifically us federal laws require pharmaceutical manufacturers pay certain statutorilyprescribed rebates state medicaid programs prescription drugs reimbursed state medicaid plans efforts states seek additional rebates affect abbvie 's business similarly veterans health care act prerequisite participation medicaid federal health care programs requires manufacturers extend additional discounts pharmaceutical products various federal agencies including united states department veterans affairs department defense public health service entities institutions addition recent legislative changes would require similarly discounted prices offered tricare program beneficiaries veterans health care act also established b drug discount program requires pharmaceutical manufacturers provide products reduced prices various designated health care entities facilities united states states also generic substitution legislation requiring permitting dispensing pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed addition federal government follows diagnosisrelated group drg payment system certain institutional services provided medicare medicaid implemented prospective payment system pps services delivered hospital outpatient nursing home home health settings drg pps entitle health care facility fixed reimbursement based diagnosis andor procedure rather actual costs incurred patient treatment thereby increasing incentive facility limit control expenditures many health care products medicare reimburses part b drugs based average sales price plus certain percentage account physician administration costs reduced hospital outpatient setting medicare enters contracts private plans negotiate prices patientadministered medicine delivered part patient protection affordable care act health care education reconciliation act together affordable care act abbvie pays fee related pharmaceuticals sales government programs addition abbvie provides discount branded prescription drugs sold patients fall medicare part coverage gap donut hole affordable care act also includes provisions known physician payments sunshine act require manufacturers drugs biologics covered medicare medicaid record transfers value physicians teaching hospitals report data centers medicare medicaid services subsequent public disclosure similar reporting requirements also enacted state level united states increasing number countries worldwide either adopted considering similar laws requiring disclosure interactions health care professionals failure report appropriate data may result civil criminal fines andor penalties abbvie expects debate continue government levels worldwide marketing availability method delivery payment health care products services abbvie believes future legislation regulation markets serves could affect access health care products services increase rebates reduce prices rate price increases health care products services change health care delivery systems create new fees obligations pharmaceuticals industry require additional reporting disclosure possible predict extent abbvie health care industry general might affected matters discussed european union european union adopted directives legislation governing labeling advertising distribution supply pharmacovigilance marketing pharmaceutical products legislation provides mandatory standards throughout european union permits member states supplement standards additional regulations european governments also regulate pharmaceutical product prices control national health care systems fund large part cost products consumers result patients unlikely use pharmaceutical product reimbursed government many european countries government either regulates pricing new product launch subsequent launch direct price controls reference pricing recent years many countries also imposed new additional cost containment measures pharmaceutical products differences national pricing regimes create price differentials within european union lead significant parallel trade pharmaceutical products form kmost governments also promote generic substitution mandating permitting pharmacist substitute different manufacturer 's generic version pharmaceutical product one prescribed permitting mandating health care professionals prescribe generic versions certain circumstances many governments also following similar path biosimilar therapies addition governments use reimbursement lists limit pharmaceutical products eligible reimbursement national health care systems japan japan national health insurance system maintains drug price list specifying pharmaceutical products eligible reimbursement ministry health labour welfare sets prices products list government generally introduces price cut rounds every year also mandates price decreases specific products new products judged innovative useful indicated pediatric use target orphan small population diseases however may eligible pricing premium government also promoted use generics available emerging markets many emerging markets take steps reduce pharmaceutical product prices cases direct price controls others promotion genericbiosimilar alternatives branded pharmaceuticals since abbvie markets products worldwide certain products local nature variations product lines must also meet local regulatory requirements certain additional risks inherent conducting business outside united states including price currency exchange controls changes currency exchange rates limitations participation local enterprises expropriation nationalization governmental action regulation medical devices medical devices subject regulation fda state agencies foreign government health authorities fda regulations well various us federal state laws govern development clinical testing manufacturing labeling record keeping marketing medical device products agencies united states abbvies medical device product candidates including abbvies breast implants must undergo rigorous clinical testing extensive government regulatory clearance approval process prior sale united states countries lengthy process clinical development submissions clearance approval continuing need compliance applicable laws regulations require expenditure substantial resources regulatory clearance approval obtained may limited scope may significantly limit indicated uses product may marketed cleared approved products manufacturers subject ongoing review discovery previously unknown problems products may result restrictions manufacture sale andor use require withdrawal market united states abbvies medical device products subject extensive regulation fda united states unless exemption applies medical device abbvie markets united states must k clearance premarket approval application pma accordance ffdca implementing regulations fda classifies medical devices one three classes depending degree risk associated medical device extent controls needed ensure safety effectiveness devices deemed pose lower risk placed either class class ii devices deemed fda pose greatest risk lifesustaining lifesupporting implantable devices device deemed substantially equivalent previously cleared k device placed class iii general class iii device marketed united states unless fda approves device submission pma changes device subsequent initial fda approval must also reviewed approved fda majority abbvies medical device products including abbvies breast implants regulated class iii medical devices class iii device may significant additional obligations imposed conditions approval time takes obtain approval long compliance regulatory requirements assured periodic unannounced facility inspections fda regulatory authorities inspections may include manufacturing facilities abbvies subcontractors thirdparty manufacturers failure comply applicable regulatory requirements result enforcement action fda may include following sanctions warning letters untitled letters fines injunctions civil penalties recall seizure abbvie products operating restrictions partial suspension total shutdown production refusing abbvie request k clearance pma approval new products withdrawing k clearance pma approvals already granted criminal prosecution clinical trial almost always required support pma application sometimes required k premarket notification clinical trials generally require submission application investigational device exemption ide must supported appropriate data animal laboratory testing results showing safe test device humans testing protocol scientifically sound study sponsor must obtain approval ide fda must also obtain approval study institutional review board irb overseeing trial results clinical testing may sufficient obtain approval investigational device device approved manufacture distribution device remains subject continuing regulation fda including quality system regulation requirements involve design testing control documentation quality assurance procedures manufacturing process medical device manufacturers subcontractors required register establishments list manufactured devices fda subject periodic unannounced inspections fda certain state agencies compliance regulatory requirements manufacturers must also report fda devices may caused contributed death serious injury malfunctioned way could likely cause contribute death serious injury manufacturer conducts field correction product recall removal reduce risk health posed device remedy violation ffdca may present health risk fda continues regulate device labeling prohibits promotion products unapproved offlabel uses along labeling restrictions european union medical device products marketed european union must comply requirements medical device regulation mdr come effect may mdr provides regulatory oversight respect design manufacture clinical trials labeling adverse event reporting medical devices ensure medical devices marketed european union safe effective intended uses medical devices comply mdr entitled bear conformit europenne marking evidencing compliance may marketed european union failure comply domestic international regulatory requirements could affect abbvies ability market sell abbvies products countries environmental matters abbvie believes operations comply material respects applicable laws regulations concerning environmental protection regulations federal state environmental laws impose stringent limitations emissions discharges environment various manufacturing operations abbvie 's capital expenditures pollution control approximately million operating expenditures approximately million capital expenditures pollution control estimated approximately million operating expenditures estimated approximately million abbott identified one many potentially responsible parties investigations andor remediations several locations united states including puerto rico comprehensive environmental response compensation liability act commonly known superfund locations transferred abbvie connection separation distribution abbvie become party investigations remediations abbott also engaged remediation several sites transferred abbvie connection separation distribution cooperation environmental protection agency similar agencies feasible predict certainty final costs related investigations remediation activities abbvie believes costs together expenditures maintain compliance applicable laws regulations concerning environmental protection material adverse effect company 's financial position cash flows results operations employees abbvie employed approximately employees countries january outside united states abbvie 's employees represented unions works councils abbvie believes good relations employees human capital management attracting retaining providing meaningful growth development opportunities abbvie 's employees critical company 's success making remarkable impact peoples lives around world abbvie leverages numerous resources identify enhance strategic leadership capability foster employee engagement create culture diverse talent productive engaged abbvie invests employees competitive compensation benefits employee support programs offers bestinclass development leadership opportunities abbvie developed deep talent base ongoing investment functional leadership training sourcing worldclass external talent ensuring sustainable talent pipeline abbvie continuously cultivates enhances working culture embraces equality diversity inclusion fundamental company 's mission form kattracting developing talent attracting developing highperforming talent essential abbvies continued success abbvie implements detailed talent attraction strategies emphasis stem skill sets diverse talent base critical skillsets including drug discovery clinical development market access business development abbvie also invests competitive compensation benefits programs addition offering comprehensive suite benefits ranging medical dental coverage retirement disability life insurance programs abbvie also provides health promotion programs mental health awareness campaigns employee assistance programs several countries financial wellness support onsite health screenings immunizations several countries onsite fitness rehabilitation centers addition abbvie employee assistance fund part abbvie foundation supports two programs global employees abbvie possibilities scholarship children employees annual merit based scholarship use accredited colleges universities vocationaltechnical schools employee relief program financial assistance support short term needs employees faced largescale disasters eg hurricane individual disasters eg home fire financial hardship eg death spouse finally abbvie empowers managers teams tools tips guidelines effectively managing workloads managing teams distance supporting flexible work practices new abbvie employees given tailored onboarding experience faster integration support performance abbvie 's mentorship program allows employees selfnominate mentors mentees facilitates meaningful relationships supporting employees career development goals abbvie also provides structured broadbased development opportunities focusing highperformance skills leadership training abbvie 's talent philosophy holds leaders accountable building highperforming organization company provides development opportunities levels leadership abbvie 's learn develop perform program offers yearlong selfdirected leadership education supplemented tools resources leverages leaders role models teachers addition foundation abbvie 's leadership pipeline company 's professional development programs attract graduates postgraduates postdoctoral talent participate formal development programs lasting three years objective strengthening functional leadership capabilities abbvie also recently introduced additional development support senior leaders managing increased integration operational complexity following transformational acquisition allergan culture abbvies shared values transforming lives acting integrity driving innovation embracing diversity inclusion serving community form core company 's culture abbvie articulates behaviors associated values ways work core set working behaviors emphasize company achieves results equally important achieving ways work designed ensure every abbvie employee aware company 's cultural expectations abbvie integrates ways work talent processes forming basis assessing performance prioritizing development ultimately rewarding employees abbvie believes culture creates strong engagement measured regularly confidential third party allemployee survey engagement supports abbvies mission making remarkable impact peoples lives equity equality diversity inclusion eedi cornerstone abbvies human capital management approach prioritize fostering inclusive diverse workforce abbvie adopted fiveyear equality diversity inclusion roadmap defines key global focus areas objectives associated initiatives includes implementation plans organized business function geography abbvies senior leaders adopted formal goals aligned executing strategy past year abbvie 's board directors prioritized oversight abbvie 's response us racial justice movement including overseeing internal programs designed ensure abbvie attracting retaining developing diverse talent june women represented percent management positions globally united states percent abbvie 's workforce comprised members historically underrepresented populations increase abbvie committed pay equity conducts pay equity analyses annually critical component abbvie 's strategy instill inclusive mindset abbvie leaders employees company realize full value diverse workforce recruitment retirement abbvie recently launched new toolkit people manage others reinforce importance eedi business educate leaders inclusive recruiting practices modeling inclusive behavior encourage participation company 's inclusive culture learning opportunities abbvie 's employee resource groups also help company nurture inclusive culture building community hosting awareness events providing leadership career opportunities abbvie reiterated commitment racial equality social justice appointing two additional senior level positions drive change awareness companywide taking deliberate steps ensure abbvie leads example promoting racial equity described company 's website httpswwwabbviecomourcompanyourprinciplesourcommitmenttoracialjusticehtml covid health safety abbvie effectively prioritized health safety employees covid pandemic continuing drive strong business performance abbvie also implemented among things temporary office facility closures establishment new safety cleaning protocols procedures regular communication regarding effect pandemic abbvie 's business employees establishment physical distancing procedures modification workspaces provision personal protective equipment cleaning supplies employees temperature screening company locations variety testing resources including onsite athome testing covid case management programs remote working accommodations related services support employees needs flexibility addition covid covered event abbvie employee assistance fund 's employee relief program entitling eligible abbvie employees families financial assistance pay mortgagerent utilities food childcare medical expenses covered insurance abbvie also provided paid leave support accommodations company 's employees relevant medical pharmaceutical rd science public health public safety skills knowledge training experience desired requested mandated serve volunteers pandemic lastly abbvies commitment employees evidenced workforce reductions salary reductions associated covid internet information copies abbvie 's annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act available free charge abbvie 's investor relations website wwwabbvieinvestorcom soon reasonably practicable abbvie electronically files material furnishes securities exchange commission sec abbvie 's corporate governance guidelines outline directorship qualifications code business conduct charters abbvie 's audit committee compensation committee nominations governance committee public policy committee available abbvie 's investor relations website wwwabbvieinvestorcom item risk factors carefully consider following risks information evaluating abbvie abbvie 's common stock following risks could materially adversely affect abbvie 's results operations financial condition cash flows risk factors generally separated two groups risks related abbvie 's business risks related abbvie 's common stock based information currently known abbvie believes following information identifies significant risk factors affecting categories risks however risks uncertainties abbvie faces limited set forth risk factors described may order importance probability occurrence additional risks uncertainties presently known abbvie abbvie currently believes immaterial may also adversely affect business addition past financial performance may reliable indicator future performance historical trends used anticipate results trends future periods following risks uncertainties develops actual events events could material adverse effect abbvie 's business results operations financial condition cash flows case trading price abbvie 's common stock could decline risks related abbvie 's business public health outbreaks epidemics pandemics coronavirus covid could future adverse impact abbvies operations financial condition public health outbreaks epidemics pandemics could future adverse impact abbvies operations financial condition continuing pandemic caused novel strain coronavirus covid caused many countries including united states declare national emergencies implement preventive measures travel bans shelter place total lockdown orders eased continuation reimplementation bans orders remains uncertain covid pandemic caused abbvie modify business practices including instituting remote work many abbvies employees abbvie may take actions may required government authorities abbvie determines best interests abbvies employees patients customers business partners impact covid abbvies operations including among others manufacturing supply chain sales marketing commercial clinical trial operations todate material abbvie experienced lower form knew patient starts across therapeutic portfolio impact covid abbvie longterm uncertain predicted confidence extent adverse impact covid abbvies operations depend extent severity continued spread covid globally timing nature actions taken respond covid resulting economic consequences ultimately outbreak could material adverse impact abbvies operations financial condition expiration loss patent protection licenses may adversely affect abbvie 's future revenues operating earnings abbvie relies patent trademark intellectual property protection discovery development manufacturing sale products particular patent protection aggregate important abbvie 's marketing pharmaceutical products united states major markets outside united states patents covering abbvie products normally provide market exclusivity important profitability many abbvie 's products patents certain products expire abbvie could face competition lower priced generic biosimilar products expiration loss patent protection product typically followed promptly substitutes may significantly reduce sales product short amount time abbvie 's competitive position compromised generics biosimilars otherwise could material adverse effect abbvie 's business results operations addition proposals emerge time time legislation encourage early rapid approval generic drugs biosimilars proposals enacted law could increase impact generic competition abbvie 's principal patents trademarks described greater detail item businessintellectual property protection regulatory exclusivity item management 's discussion analysis financial condition results operationsresults operations litigation regarding patents described item legal proceedings united states composition matter patent humira abbvie 's largest product worldwide net revenues approximately billion expired december equivalent european union patent expired majority european union countries october abbvie 's major products could lose patent protection earlier expected could adversely affect abbvie 's future revenues operating earnings third parties government authorities may challenge seek invalidate circumvent abbvie 's patents patent applications example manufacturers generic pharmaceutical products file may continue file abbreviated new drug applications fda seeking market generic forms abbvie 's products prior expiration relevant patents owned licensed abbvie asserting patents invalid unenforceable andor infringed addition petitioners filed may continue file challenges validity abbvie patents leahysmith america invents act created inter partes review post grant review procedures challenging patent validity administrative proceedings united states patent trademark office although challenges abbvie 's intellectual property come businesses governments may also challenge intellectual property rights example court decisions potential legislation relating patents legislation regarding biosimilars regulatory initiatives may result erosion intellectual property protection addition certain governments outside united states indicated compulsory licenses patents may sought domestic policies basis national emergencies hivaids triggered compulsory licenses could diminish eliminate sales profits jurisdictions negatively affect abbvie 's results operations abbvie normally responds challenges vigorously defending patents including filing patent infringement lawsuits patent litigation administrative proceedings challenges abbvie 's patents costly unpredictable may deprive abbvie market exclusivity patented product extent abbvie 's intellectual property successfully challenged circumvented weakened extent intellectual property allow abbvie compete effectively abbvie 's business suffer extent countries enforce abbvie 's intellectual property rights require compulsory licensing abbvie 's intellectual property abbvie 's future revenues operating earnings reduced third party 's intellectual property may prevent abbvie selling products material adverse effect abbvie 's future profitability financial condition third parties may claim abbvie product infringes upon intellectual property resolving intellectual property infringement claim costly time consuming may require abbvie enter license agreements abbvie guarantee would able obtain license agreements commercially reasonable terms successful claim patent intellectual property infringement could subject abbvie significant damages injunction preventing manufacture sale use affected abbvie product products events could material adverse effect abbvie 's profitability financial condition significant event adversely affects humira revenues could material negative impact abbvie 's results operations cash flows humira accounted approximately abbvie 's total net revenues significant event adversely affects humira 's revenues could material adverse impact abbvie 's results operations cash flows events could include loss patent protection humira described expiration loss patent protection licenses may adversely affect abbvies future revenues operating earnings commercialization biosimilars humira discovery previously unknown side effects impaired efficacy increased competition introduction new effective less expensive treatments discontinuation removal market humira reason abbvie 's research development efforts may succeed developing marketing commercially successful products technologies may cause revenues profitability decline remain competitive abbvie must continue launch new products new indications andor brand extensions existing products launches must generate revenue sufficient cover substantial research development costs replace revenues profitable products lost displaced competing products therapies failure would material adverse effect abbvie 's revenue profitability accordingly abbvie commits substantial effort funds resources research development must make ongoing substantial expenditures without assurance efforts commercially successful high rate failure biopharmaceutical industry inherent research development new products failure occur point research development process including significant funds invested products appear promising development may fail reach market numerous reasons including failure demonstrate effectiveness safety concerns superior safety efficacy competing therapies failure achieve positive clinical preclinical outcomes beyond current standards care inability obtain necessary regulatory approvals delays approval new products new indications limited scope approved uses excessive costs manufacture failure obtain maintain intellectual property rights infringement intellectual property rights others decisions research studies made early development process pharmaceutical product candidate affect marketing strategy candidate receives approval detailed studies may demonstrate additional benefits help marketing also consume time resources may delay submitting pharmaceutical product candidate approval abbvie guarantee proper balance speed testing made respect pharmaceutical product candidate decisions area would adversely affect abbvie 's future results operations even abbvie successfully develops markets new products enhancements existing products may quickly rendered obsolete changing clinical preferences changing industry standards competitors ' innovations abbvie 's innovations may accepted quickly marketplace existing clinical practices uncertainty thirdparty reimbursement abbvie state certainty whether products development launched whether able develop license otherwise acquire compounds products whether products commercially successful failure launch successful new products new indications existing products may cause abbvie 's products become obsolete causing abbvie 's revenues operating results suffer portion abbvie 's nearterm pharmaceutical pipeline relies collaborations third parties may adversely affect development sale products abbvie depends alliances joint ventures pharmaceutical biotechnology companies portion products nearterm pharmaceutical pipeline failures parties meet contractual regulatory obligations abbvie disruption relationships abbvie third parties could adverse effect abbvie 's pharmaceutical pipeline business addition abbvie 's collaborative relationships research development extend many years may give rise disputes regarding relative rights obligations revenues abbvie collaboration partners including ownership intellectual property associated rights obligations could result loss intellectual property rights protection delay development sale potential pharmaceutical products lead lengthy expensive litigation administrative proceedings arbitration form kbiologics carry unique risks uncertainties could negative impact future results operations successful discovery development manufacturing sale biologics long expensive uncertain process unique risks uncertainties biologics example access supply necessary biological materials cell lines may limited governmental regulations restrict access regulate transport use materials addition development manufacturing sale biologics subject regulations often complex extensive regulations applicable pharmaceutical products manufacturing biologics especially large quantities often complex may require use innovative technologies manufacturing also requires facilities specifically designed validated purpose sophisticated quality assurance quality control procedures biologics also frequently costly manufacture production inputs derived living animal plant material biologics made synthetically failure successfully discover develop manufacture sell biologicsincluding humiracould adversely impact abbvie 's business results operations abbvie 's biologic products subject competition biosimilars biologics price competition innovation act creates framework approval biosimilars united states could allow competitors reference data biologic products already approved europe european commission granted marketing authorizations several biosimilars pursuant set general product classspecific guidelines biosimilar approvals issued past years addition companies developing biosimilars countries could compete abbvies biologic products including humira competitors obtain marketing approval biosimilars referencing abbvies biologic products abbvies products may become subject competition biosimilars attendant competitive pressure consequences expiration successful challenge abbvies applicable patent rights could also trigger competition products assuming relevant exclusivity period expired result abbvie could face litigation administrative proceedings respect validity andor scope patents relating biologic products new products technological advances abbvie 's competitors may negatively affect abbvie 's results operations abbvie competes researchbased pharmaceutical biotechnology companies discover manufacture market sell proprietary pharmaceutical products biologics example humira competes antitnf products competitive products intended treat number disease states mavyretmaviret competes available hepatitis c treatment options addition past years number companies started develop successfully developed andor currently marketing products positioned competitors botox competitors may introduce new products develop technological advances compete abbvies products therapeutic areas immunology hematologic oncology aesthetics neuroscience eye care women 's health abbvie predict certainty timing impact introduction competitors new products technological advances competing products may safer effective effectively marketed sold lower prices superior performance features abbvies products could negatively impact abbvies business results operations manufacture many abbvie 's products highly exacting complex process abbvie one suppliers encounters problems manufacturing abbvie 's products abbvie 's business could suffer manufacture many abbvie 's products highly exacting complex process due part strict regulatory requirements problems may arise manufacturing variety reasons including equipment malfunction failure follow specific protocols procedures problems raw materials delays related construction new facilities expansion existing facilities including intended support future demand abbvie 's products changes manufacturing production sites limits manufacturing capacity due regulatory requirements changes types products produced physical limitations could inhibit continuous supply manmade natural disasters environmental factors problems arise production batch product batch product may discarded abbvie may experience product shortages incur added expenses could among things lead increased costs lost revenue damage customer relations time expense spent investigating cause depending cause similar losses respect batches products problems discovered product released market recall product liability costs may also incurred abbvie uses number products pharmaceutical biologic manufacturing processes sourced single suppliers interruption supply products could adversely affect abbvie 's business results operations abbvie uses number products pharmaceutical biologic manufacturing processes sourced single suppliers failure singlesource suppliers fulfill contractual obligations timely manner result regulatory noncompliance physical disruption manufacturing site may impair abbvie 's ability deliver products customers timely competitive basis could adversely affect abbvie 's business results operations finding alternative supplier could take significant amount time involve significant expense due nature products need obtain regulatory approvals abbvie guarantee able reach agreement alternative providers regulatory authorities would approve abbvie 's use alternatives abbvie however carry business interruption insurance provides degree protection case failure singlesource supplier certain aspects abbvies operations highly dependent upon third party service providers abbvie relies suppliers vendors third party service providers research develop manufacture commercialize promote sell products reliance third party manufacturers reduces abbvies oversight control manufacturing process third party providers subject legal regulatory requirements privacy security risks market risks failure critical third party service provider meet obligations could material adverse impact abbvies operations results third party service providers violated alleged violated laws regulations performance obligations abbvie possible abbvie could suffer financial reputational harm negative outcomes including possible legal consequences significant safety efficacy issues could arise abbvie 's products could material adverse effect abbvie 's revenues financial condition pharmaceutical products receive regulatory approval based data obtained controlled clinical trials limited duration following regulatory approval products used longer periods time many patients investigators may also conduct additional perhaps extensive studies new safety efficacy issues reported new scientific information becomes available including results postmarketing phase trials governments change standards regarding safety efficacy labeling abbvie may required amend conditions use product example abbvie may voluntarily provide required provide updated information product 's label narrow approved indication either could reduce product 's market acceptance safety efficacy issues abbvie product arise sales product could halted abbvie regulatory authorities regulatory action could taken regulatory authorities safety efficacy issues affecting suppliers ' competitors ' products also may reduce market acceptance abbvie 's products new data abbvie 's products products similar products could negatively impact demand abbvie 's products due real perceived safety issues uncertainty regarding efficacy cases could result product withdrawal furthermore new data information including information product misuse may lead government agencies professional societies practice management groups organizations involved various diseases publish guidelines recommendations related use abbvie 's products use related therapies place restrictions sales guidelines recommendations may lead lower sales abbvie 's products abbvie subject product liability claims lawsuits may adversely affect business results operations ordinary course business abbvie subject product liability claims lawsuits alleging abbvie 's products products companies promotes resulted could result unsafe condition injury patients example lawsuits pending allergan abbvies newly acquired subsidiary certain current former officers alleging made misrepresentations omissions regarding allergans textured breast implants product liability claims lawsuits safety alerts product recalls regardless ultimate outcome may material adverse effect abbvie 's business results operations reputation ability attract retain customers consequences may also include additional costs decrease market share product question lower income exposure claims product liability losses selfinsured abbvie also subject claims legal proceedings investigations ordinary course business relate intellectual property commercial securities matters adverse outcomes claims legal proceedings investigations may also adversely affect abbvies business results operations additionally allergan named defendant approximately matters relating promotion sale prescription opioid pain form krelievers additional suits may filed see note legal proceedings contingencies consolidated financial statements included item financial statements supplementary data abbvie predict outcome proceedings abbvie subject costcontainment efforts pricing pressures could cause reduction future revenues operating earnings changes terms rebate chargeback programs common pharmaceuticals industry could material adverse effect abbvie 's operations costcontainment efforts governments private organizations described greater detail item businessregulationcommercialization distribution manufacturing extent cost containment efforts offset greater demand increased patient access health care factors abbvie 's future revenues operating earnings reduced united states european union countries abbvie 's business experienced downward pressure product pricing pressure could increase future abbvie subject increasing public legislative pressure respect pharmaceutical pricing united states practices managed care groups institutional governmental purchasers united states federal laws regulations related medicare medicaid including medicare prescription drug improvement modernization act patient protection affordable care act contribute pricing pressures potential continuing changes health care system united states increased purchasing power entities negotiate behalf medicare medicaid private sector beneficiaries could result additional pricing pressures numerous major markets worldwide government plays significant role funding health care services determining pricing reimbursement pharmaceutical products consequently markets abbvie subject government decisionmaking budgetary actions respect products particular many european countries ongoing governmentmandated price reductions many pharmaceutical products abbvie anticipates continuing pricing pressures europe differences countries pricing regulations could lead thirdparty crossborder trading abbvie 's products results reduction future revenues operating earnings rebates related government programs feeforservice medicaid medicaid managed care programs arise laws regulations abbvie predict additional government initiatives contain health care costs factors could lead new modified regulatory requirements include higher incremental rebates discounts rebate discount programs arise contractual agreements private payers various factors including market factors ability private payers control patient access products may provide payers leverage negotiate higher additional rebates discounts could material adverse effect abbvie 's operations abbvie subject numerous governmental regulations costly comply regulations develop compliant products processes abbvie 's products subject rigorous regulation numerous international supranational federal state authorities described item businessregulationdiscovery clinical development businessregulationcommercialization distribution manufacturing business regulationmedical devices process obtaining regulatory approvals market pharmaceutical product costly time consuming approvals might granted future products additional indications uses existing products timely basis delays receipt failure obtain approvals future products new indications uses could result delayed realization product revenues reduction revenues substantial additional costs addition abbvie guarantee remain compliant applicable regulatory requirements approval obtained product requirements include among things regulations regarding manufacturing practices product labeling advertising postmarketing reporting including adverse event reports field alerts due manufacturing quality concerns abbvie must incur expense spend time effort ensure compliance complex regulations possible regulatory actions could result substantial modifications abbvie 's business practices operations refunds recalls seizures abbvie 's products total partial shutdown production one abbvie 's suppliers ' facilities abbvie supplier remedies alleged violation inability obtain future approvals withdrawals suspensions current products market events could disrupt abbvie 's business material adverse effect business results operations laws regulations affecting government benefit programs could impose new obligations abbvie require change business practices restrict operations future health care industry subject various federal state international laws regulations pertaining government benefit programs reimbursement rebates price reporting regulation health care fraud abuse united states laws include antikickback false claims laws medicaid rebate statute veterans health care act us physician payments sunshine act tricare program government pricing rules applicable medicaid medicare part b b drug pricing program individual state laws relating pricing sales marketing practices violations laws may punishable criminal andor civil sanctions including instances substantial fines imprisonment exclusion participation federal state health care programs including medicare medicaid veterans administration health programs laws regulations broad scope subject change evolving interpretations could require abbvie incur substantial costs associated compliance alter one sales marketing practices addition violations laws allegations violations could disrupt abbvie 's business result material adverse effect business results operations international nature abbvie 's business subjects additional business risks may cause revenue profitability decline abbvie 's business subject risks associated business internationally including emerging markets net revenues outside united states made approximately abbvie 's total net revenues risks associated abbvie 's operations outside united states include fluctuations currency exchange rates changes medical reimbursement policies programs multiple legal regulatory requirements subject change could restrict abbvie 's ability manufacture market sell products differing local product preferences product requirements trade protection measures import export licensing requirements international trade disruptions disputes difficulty establishing staffing managing operations differing labor regulations potentially negative consequences changes interpretations tax laws political economic instability including result united kingdoms exit european union covid pandemic sovereign debt issues price currency exchange controls limitations participation local enterprises expropriation nationalization governmental action regulation inflation recession fluctuations interest rates restrictions transfers funds potential deterioration economic position credit quality certain nonus countries including europe latin america potential penalties adverse consequences violations anticorruption antibribery similar laws regulations including united states foreign corrupt practices act united kingdom bribery act events contemplated risks may individually aggregate material adverse effect abbvie 's revenues profitability form kif abbvie effectively profitably commercialize products abbvie 's revenues financial condition could adversely affected abbvie must effectively profitably commercialize principal products creating meeting continued market demand achieving market acceptance generating product sales ensuring active pharmaceutical ingredients product finished product manufactured sufficient quantities compliance requirements fda similar foreign regulatory agencies acceptable quality pricing meet commercial demand ensuring entire supply chain efficiently consistently delivers abbvie 's products customers commercialization abbvie products may successful due among things unexpected challenges competitors new safety issues concerns reported may impact narrow approved indications relative price abbvie 's product compared alternative treatment options changes product 's label restrict marketing commercialization abbvie 's principal products unsuccessful abbvie 's ability generate revenue product sales adversely affected abbvie may acquire businesses license rights technologies products form alliances dispose assets could cause incur significant expenses could negatively affect profitability abbvie may pursue acquisitions technology licensing arrangements joint ventures strategic alliances dispose assets part business strategy abbvie may complete transactions timely manner costeffective basis may realize expected benefits abbvie successful making acquisition products technologies acquired may successful may require significantly greater resources investments originally anticipated abbvie may able integrate acquisitions successfully existing business could incur assume significant debt unknown contingent liabilities abbvie could also experience negative effects reported results operations acquisition dispositionrelated charges amortization expenses related intangibles charges impairment longterm assets effects could cause deterioration abbvie 's credit rating result increased borrowing costs interest expense additionally changes abbvie 's structure operations revenues costs efficiency resulting major transactions acquisitions divestitures mergers alliances joint ventures restructurings strategic initiatives may result greater expected costs may take longer expected complete encounter difficulties including need regulatory approval appropriate abbvie dependent wholesale distributors distribution products united states accordingly results operations could adversely affected encounter financial difficulties three wholesale distributors mckesson corporation cardinal health inc amerisourcebergen corporation accounted substantially abbvie 's sales united states one significant wholesale distributors encounters financial difficulties distributor may decrease amount business abbvie abbvie may unable collect amounts distributor owes timely basis could negatively impact abbvie 's business results operations abbvie debt obligations could adversely affect business ability meet obligations amount debt abbvie incurred intends incur could important consequences abbvie investors consequences include among things requiring portion abbvie 's cash flow operations make interest payments debt reducing cash flow available fund capital expenditures corporate purposes grow abbvie 's business particular abbvie incurred significant debt connection acquisition allergan abbvies substantially increased indebtedness higher debt equity ratio result acquisition may exacerbate risks effect among things reducing flexibility respond changing business economic conditions andor lowering credit ratings extent abbvie incurs additional indebtedness interest rates increase risks could increase addition abbvie 's cash flow operations may sufficient repay outstanding debt becomes due abbvie may able borrow money sell assets otherwise raise funds acceptable terms refinance debt abbvie may need additional financing future meet capital needs make opportunistic acquisitions financing may available favorable terms abbvie may need seek additional financing general corporate purposes example may need increase investment research development activities need funds make acquisitions abbvie may unable obtain desired additional financing terms favorable abbvie loses investment grade credit rating adequate funds available acceptable terms abbvie may unable fund expansion successfully develop enhance products respond competitive pressures could negatively affect abbvie 's business abbvie raises additional funds issuing debt entering credit facilities may subject limitations operations due restrictive covenants failure comply covenants could adversely affect abbvie 's business abbvie depends information technology failure systems could material adverse effect abbvie 's business abbvie relies sophisticated software applications complex information technology systems operate business systems potentially vulnerable malicious intrusion random attack loss data privacy disruption degradation breakdown data privacy security breaches employees others resulted may future result failure critical business operations may cause sensitive data including intellectual property trade secrets personal information belonging abbvie patients customers business partners exposed unauthorized persons public date abbvies business operations materially impacted incidents although abbvie invested protection data information technology also monitors systems ongoing basis assurance efforts prevent material breakdowns breaches abbvie 's information technology systems could adversely affect abbvie 's business adverse consequences could include loss revenue loss critical sensitive information abbvies thirdparty providers databases systems could also result legal financial reputational business harm abbvie potentially substantial remediation costs connection acquisition allergan abbvies balances intangible assets including developed product rights goodwill acquired increased significantly balances subject impairment testing may result impairment charges adversely affect abbvies results operations financial condition significant amount abbvies total assets related acquired intangibles goodwill december carrying value abbvies developed product rights intangible assets billion carrying value abbvies goodwill billion abbvies developed product rights stated cost less accumulated amortization abbvie determines original fair value amortization periods developed product rights based assessment various factors impacting estimated useful lives cash flows acquired products significant adverse changes factors require abbvie perform impairment test affected asset evidence impairment exists require abbvie take impairment charge respect asset assets impaired abbvie may adjust remaining useful lives charge could material adverse effect abbvies results operations financial condition abbvies significant intangible assets include inprocess research development iprd intangible projects acquired recent business combinations indefinitelived intangible assets goodwill abbvies iprd intangible assets tested impairment annually events occur circumstances change could potentially reduce fair value reporting unit intangible asset impairment testing compares fair value reporting unit intangible asset carrying amount goodwill iprd impairment would recorded operating income could material adverse effect abbvies results operations financial condition failure attract retain highly qualified personnel could affect abbvies ability successfully develop commercialize products abbvies success largely dependent continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical research development rd governmental regulation commercialization competition qualified personnel biopharmaceutical field intense abbvie sure able attract retain quality personnel costs materially increase factors material adverse effect abbvie 's profitability financial condition many factors affect abbvie 's results operations cash flows financial condition including changes interpretations laws regulations including changes accounting standards taxation requirements product marketing application standards data privacy laws particularly european union united states environmental laws differences fair value measurement assets liabilities actual value particularly pension postemployment benefits stockbased compensation intangibles goodwill contingent liabilities litigation contingent consideration absence recorded amount amount recorded minimum compared actual amount changes rate inflation including cost raw materials commodities supplies interest rates market value abbvie 's equity investments performance investments held employee benefit trusts changes creditworthiness counterparties transact business provide services abbvie employee benefit trusts environmental liabilities connection abbvies manufacturing processes distribution logistics including handling hazardous materials changes ability third parties provide information technology accounting human resources payroll outsourced services abbvie meet contractual obligations abbvie changes business economic political conditions including war political instability terrorist attacks threat future terrorist activity related military action natural disasters cost availability insurance due foregoing events labor disputes strikes slowdowns forms labor union activity pressure thirdparty interest groups risks related abbvie 's common stock abbvie guarantee timing amount payment dividends common stock although abbvie expects pay regular cash dividends timing declaration amount payment future dividends stockholders fall within discretion abbvie 's board directors board 's decisions regarding payment dividends depend many factors abbvie 's financial condition earnings capital requirements debt service obligations industry practice legal requirements regulatory constraints factors board deems relevant information see item market registrant 's common equity related stockholder matters issuer purchases equity securities abbvie 's ability pay dividends depend ongoing ability generate cash operations access capital markets abbvie guarantee continue pay dividend future abbvie stockholder 's percentage ownership abbvie may diluted future future stockholder 's percentage ownership abbvie may diluted equity issuances capital market transactions equity awards abbvie granting abbvie 's directors officers employees acquisitions purposes abbvie 's employees options purchase shares common stock result conversion abbott stock options whole part abbvie stock options abbvie anticipates compensation committee grant additional stock options stockbased awards employees awards dilutive effect abbvie 's earnings per share could adversely affect market price abbvie 's common stock time time abbvie issue additional options stockbased awards employees abbvie 's employee benefits plans addition abbvie 's amended restated certificate incorporation authorizes abbvie issue without approval abbvie 's stockholders one classes series preferred stock designation powers preferences relative participating optional special rights including preferences abbvie 's common stock respecting dividends distributions abbvie 's board directors generally may determine terms one classes series preferred stock could dilute voting power reduce value abbvie 's common stock example abbvie could grant holders preferred stock right elect number abbvie 's directors events happening specified events right veto specified transactions similarly repurchase redemption rights liquidation preferences abbvie could assign holders preferred stock could affect residual value common stock certain provisions abbvie 's amended restated certificate incorporation amended restated bylaws delaware law may prevent delay acquisition abbvie could decrease trading price abbvie 's common stock abbvie 's amended restated certificate incorporation amended restated bylaws contain delaware law contains provisions intended deter coercive takeover practices inadequate takeover bids encouraging prospective acquirors negotiate abbvie 's board directors rather attempt hostile takeover provisions include among others inability abbvie 's stockholders call special meeting division abbvie 's board directors three classes directors class serving staggered threeyear term provision stockholders may remove directors cause ability abbvie 's directors stockholders fill vacancies abbvie 's board directors requirement affirmative vote stockholders holding least abbvie 's voting stock required amend certain provisions abbvie 's amended restated certificate incorporation abbvie 's amended restated bylaws relating number term election abbvie 's directors filling board vacancies calling special meetings stockholders director officer indemnification provisions addition section delaware general corporation law provides subject limited exceptions persons acquire affiliated person acquires outstanding voting stock delaware corporation shall engage business combination corporation including merger consolidation acquisitions additional shares threeyear period following date person affiliates becomes holder corporation 's outstanding voting stock abbvie believes provisions protect stockholders coercive otherwise unfair takeover tactics requiring potential acquirors negotiate abbvie 's board directors providing abbvie 's board directors time assess acquisition proposal provisions intended make company immune takeovers however provisions apply even offer may considered beneficial stockholders could delay prevent acquisition abbvie 's board directors determines best interests abbvie abbvie 's stockholders provisions may also prevent discourage attempts remove replace incumbent directors form kcautionary statement regarding forwardlooking statements annual report contains certain forward looking statements regarding business strategies market potential future financial performance matters words believe expect anticipate project similar expressions among others generally identify forward looking statements speak date statements made matters discussed forward looking statements subject risks uncertainties factors could cause actual results differ materially projected anticipated implied forward looking statements particular information included item business item risk factors item management 's discussion analysis financial condition results operations contain forward looking statements forward looking statement expectation belief future results events expressed expectation belief based current plans expectations abbvie management expressed good faith believed reasonable basis assurance expectation belief result achieved accomplished factors could cause actual results events differ materially anticipated include matters described item risk factors item management 's discussion analysis financial condition results operations abbvie undertake obligation update forward looking statements included annual report reflect events circumstances date hereof unless abbvie required applicable securities law item b unresolved staff comments none item properties abbvie 's corporate offices located north waukegan road north chicago illinois abbvie 's manufacturing facilities following locations united states outside united states abbott park illinois campoverde di aprilia italy barceloneta puerto rico clonshaugh ireland branchburg new jersey cork ireland campbell california galway ireland cincinnati ohio gracehollogne belgium dublin california guarulhos brazil houston texas la aurora costa rica irvine california ludwigshafen germany north chicago illinois pringy france waco texas singapore worcester massachusetts sligo ireland wyandotte michigan westport ireland leased property addition abbvie manufacturing facilities worldwide abbvie believes facilities suitable provide adequate production capacity material encumbrances abbvie 's owned properties united states including puerto rico abbvie two central distribution centers abbvie also research development facilities united states located abbott park illinois branchburg new jersey irvine california madison new jersey north chicago illinois pleasanton california redwood city california santa cruz california south san francisco california sunnyvale california cambridge massachusetts worcester massachusetts outside united states abbvie 's principal research development facilities located ludwigshafen germany liverpool united kingdom item legal proceedings information pertaining legal proceedings provided note legal proceedings contingencies consolidated financial statements included item financial statements supplementary data incorporated reference herein item mine safety disclosures applicable form kinformation executive officers following table lists abbvie 's executive officers name age position richard gonzalez chairman board chief executive officer michael e severino md vice chairman president laura j schumacher vice chairman external affairs chief legal officer henry gosebruch executive vice president chief strategy officer robert michael executive vice president chief financial officer timothy j richmond executive vice president chief human resources officer azita salekigerhardt phd executive vice president operations jeffrey r stewart executive vice president commercial operations thomas j hudson md senior vice president research development chief scientific officer elaine k sorg senior vice president us commercial operations carrie strom senior vice president abbvie president global allergan aesthetics brian l durkin vice president controller mr gonzalez chairman chief executive officer abbvie served abbotts executive vice president pharmaceutical products group july december responsible abbotts worldwide pharmaceutical business including commercial operations research development manufacturing also served president abbott ventures inc abbotts medical technology investment arm mr gonzalez joined abbott held various management positions first appointed abbvie corporate officer december dr severino abbvies vice chairman president responsible research development human resources operations corporate strategy office served executive vice president research development chief scientific officer dr severino served amgen inc senior vice president global development corporate chief medical officer vice president global development vice president therapeutic area head general medicine inflammation global clinical development joined abbvie first appointed abbvie corporate officer june dr severino also serves board avantor inc ms schumacher abbvies vice chairman external affairs chief legal officer responsible global legal health economics outcomes research corporate responsibility brand communications government affairs prior current appointment served abbvies executive vice president external affairs general counsel corporate secretary prior abbvies separation abbott ms schumacher served executive vice president general counsel abbott abbvie ms schumacher also led business development ventures early stage collaborations ms schumacher joined abbott first appointed abbvie corporate officer december serves board general dynamics corporation crowdstrike holdings inc mr gosebruch abbvie 's executive vice president chief strategy officer worked years mergers acquisitions group jp morgan securities llc serving managing director since cohead north america mr gosebruch joined abbvie first appointed abbvie corporate officer december serves board aptinyx inc mr michael abbvies executive vice president chief financial officer mr michael previously served senior vice president chief financial officer october july vice president controller march october served abbvies vice president treasurer vice president controller commercial operations vice president financial planning analysis abbott mr michael served division controller nutrition supply chain mr michael joined abbott first appointed abbvie corporate officer december mr richmond abbvies executive vice president chief human resources officer served senior vice president human resources mr richmond served abbotts divisional vice president compensation benefits group vice president talent rewards divisional vice president talent acquisition mr richmond joined abbott first appointed abbvie corporate officer december dr salekigerhardt abbvies executive vice president operations served senior vice president operations dr saleki gerhardt served abbotts vice president pharmaceuticals manufacturing supply divisional vice president quality assurance global pharmaceutical operations dr salekigerhardt joined abbott first appointed abbvie corporate officer december serves board entegris inc mr stewart abbvies executive vice president commercial operations previously served senior vice president us commercial operations abbvies president commercial operations prior abbvies separation abbott served vice president abbott proprietary pharmaceutical division united states mr stewart joined abbott first appointed abbvie corporate officer december dr hudson abbvie 's senior vice president research development chief scientific officer previously served vice president head oncology discovery early development prior joining abbvie dr hudson served ontario institute cancer research president scientific director also previously served founder director mcgill university genome quebec innovation centre assistant director whiteheadmit center genome research dr hudson first appointed abbvie corporate officer july ms sorg abbvies senior vice president us commercial operations previously served abbvies president us immunology patient services vice president immunology oncology served vice president immunology prior abbvies separation abbott abbvie ms sorg joined abbott first appointed abbvie corporate officer november prior joining abbott ms sorg served management roles eli lilly company years ms strom abbvies senior vice president abbvie president global allergan aesthetics responsible worldwide operations aesthetics franchise appointed position upon abbvies acquisition allergan first appointed abbvie corporate officer may allergan ms strom previously served senior vice president us medical aesthetics joined allergan mr durkin abbvies vice president controller mr durkin previously served vice president internal audit prior joining abbvie served vice president finance division controller abbotts vision care business controller pharmaceutical research development mr durkin joined abbott first appointed abbvie corporate officer october executive officers abbvie elected annually board directors officers elected board appointed chairman board officers either elected first meeting board directors held annual stockholder meeting appointed chairman board board meeting officer holds office successor duly elected appointed qualified officer 's death resignation removal family relationships executive officers listed form kpart ii item market registrant 's common equity related stockholder matters issuer purchases equity securities principal market principal market abbvie 's common stock new york stock exchange symbol abbv abbvie 's common stock also listed chicago stock exchange traded various regional electronic exchanges stockholders stockholders record abbvie common stock january performance graph following graph compares cumulative total returns abbvie sp index nyse arca pharmaceuticals index period december december graph assumes invested abbvie common stock index december also assumes reinvestment dividends stock price performance following graph necessarily indicative future stock price performance performance graph furnished shall deemed filed sec subject section securities exchange act shall deemed incorporated reference abbvie 's filings securities act amended dividends october abbvie 's board directors declared increase quarterly cash dividend per share per share payable february stockholders record january timing declaration amount payment dividends abbvie future within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors moreover abbvie determines pay dividend future assurance continue pay dividends amount dividends issuer purchases equity securities c total number shares units total purchased part maximum number number b average publicly approximate dollar value shares price announced shares units may units paid per share plans yet purchased period purchased unit programs plans programs october october november november december december total addition abbvie shares repurchased open market publicly announced program shares also included shares purchased open market benefit participants abbvie employee stock purchase plan october november december shares include shares surrendered abbvie satisfy minimum tax withholding obligations connection vesting exercise stockbased awards item reserved form kitem management 's discussion analysis financial condition results operations following discussion analysis financial condition abbvie inc abbvie company commentary read conjunction consolidated financial statements accompanying notes appearing item financial statements supplementary data section generally discusses items yeartoyear comparisons discussions items year toyear comparisons included found management 's discussion analysis financial condition results operations part ii item companys annual report fiscal year ended december executive overview company overview abbvie global researchbased biopharmaceutical company formed following separation abbott laboratories abbott abbvie uses expertise dedicated people unique approach innovation develop market advanced therapies address world 's complex serious diseases may abbvie completed acquisition allergan plc allergan acquisition allergan creates diversified biopharmaceutical company positioned success comprehensive product portfolio leadership positions key therapeutic areas immunology hematologic oncology aesthetics neuroscience eye care women 's health abbvie 's existing product portfolio pipeline enhanced numerous allergan assets allergan 's product portfolio benefits abbvie 's commercial strength expertise international infrastructure see note consolidated financial statements additional information acquisition subsequent acquisition date abbvie 's consolidated financial statements include assets liabilities operating results cash flows allergan abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses certain products including aesthetic products devices also sold directly physicians licensed healthcare providers united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly retailers pharmacies patients outside united states abbvie sells products primarily customers distributors depending market served certain products comarketed copromoted companies abbvie approximately employees abbvie operates single global business segment financial results abbvie 's strategy focused delivering strong financial results maximizing benefits allergan acquisition advancing investing pipeline returning value shareholders ensuring strong sustainable growth business long term company 's financial performance included delivering worldwide net revenues billion operating earnings billion diluted earnings per share cash flows operations billion worldwide net revenues increased reported basis constant currency basis included billion contributed revenues allergan acquisition growth immunology portfolio skyrizi rinvoq continued strength humira us well revenue growth imbruvica venclexta diluted earnings per share included following aftertax costs billion change fair value contingent consideration liabilities ii billion related amortization intangible assets iii billion allergan acquisition integration expenses iv billion acquired inprocess research development iprd million milestones research development rd expenses costs partially offset billion certain tax benefits additionally financial results reflected continued funding support stages abbvies pipeline assets continued investment abbvies onmarket brands october abbvie 's board directors declared quarterly cash dividend per share common stock payable february reflects increase approximately previous quarterly dividend per share common stock following closing allergan acquisition abbvie implemented integration plan designed reduce costs integrate optimize combined organization integration plan expected realize billion expected annual cost synergies threeyear period approximately realized rd selling general administrative sga cost products sold achieve integration objectives abbvie expects incur approximately billion charges costs consist severance employee benefit costs cash severance noncash severance including accelerated equity award compensation expense retention termination benefits integration expenses impact coronavirus disease covid march world health organization declared outbreak novel coronavirus covid pandemic continues spread throughout united states around world response growing public health crisis abbvie partnered global authorities support experimental use multiple abbvie assets determine efficacy treatment covid june abbvie announced entered collaboration harbour biomed utrecht university erasmus medical center develop novel antibody therapeutic prevent treat covid additionally abbvie donated million increase healthcare capacity supply critical equipment deliver food essential supplies crisis abbvie continues closely manage manufacturing supply chain resources around world help ensure patients continue receive uninterrupted supply medicines clinical trial sites monitored locally protect safety study participants staff employees impact covid abbvie 's operations date material abbvie experienced lower new patient starts across therapeutic portfolio abbvie expects matter could continue negatively impact results operations throughout duration outbreak extent covid may impact abbvie 's financial condition results operations remains uncertain strategic objectives abbvie 's mission discover develop innovative medicines products solve serious health issues today address medical challenges tomorrow achieving toptier financial performance outstanding execution abbvie intends continue advance mission number ways including maximizing benefits allergan acquisition create diversified revenue base multiple longterm growth drivers ii growing revenues leveraging abbvie 's commercial strength international infrastructure across allergan 's therapeutic areas ensuring strong commercial execution new product launches iii continuing invest expand pipeline support opportunities immunology oncology aesthetics neuroscience eye care women 's health well continued investment key onmarket products iv expanding operating margins v returning cash shareholders via strong growing dividend also reducing debt addition abbvie anticipates several regulatory submissions key data readouts key clinical trials next months abbvie expects achieve strategic objectives immunology revenue growth driven increasing market share expanding patient access skyrizi rinvoq well humira us sales growth hematologic oncology revenue growth imbruvica venclexta expansion companys revenue base additional allergan products contributing key aesthetics neuroscience portfolios effective management humira international biosimilar erosion optimization combined abbvie allergan research development commercial manufacturing operations maintaining key growth portfolios favorable impact pipeline products indications recently approved currently regulatory review approval expected products described greater detail section labeled research development included part item abbvie remains committed driving continued expansion operating margins expects achieve objective continued leverage revenue growth realization expense synergies allergan acquisition productivity initiatives supply chain ongoing efficiency programs optimize manufacturing commercial infrastructure administrative costs general corporate expenses combination abbvie allergan creates diverse entity leadership positions across immunology hematologic oncology aesthetics neuroscience women 's health eye care virology abbvie 's existing product portfolio pipeline enhanced numerous allergan assets allergan 's product portfolio benefits abbvie 's commercial strength expertise international infrastructure form kresearch development research innovation cornerstones abbvie 's business global biopharmaceutical company abbvie 's longterm success depends great extent ability continue discover develop innovative products acquire collaborate compounds currently development biotechnology pharmaceutical companies abbvie 's pipeline currently includes compounds devices indications development individually collaboration license agreements focused important specialties immunology oncology aesthetics neuroscience eye care women 's health along targeted investments cystic fibrosis programs mid latestage development following sections summarize transitions significant programs midstage development latestage development well developments significant latestage registration programs abbvie expects multiple midstage programs transition latestage programs next months significant programs developments immunology skyrizi january abbvie announced topline results phase keepsake keepsake clinical trials skyrizi adults active psoriatic arthritis psa met primary ranked secondary endpoints january abbvie announced topline results phase advance motivate induction studies skyrizi patients crohns disease met primary key secondary endpoints rinvoq february abbvie announced topline results second phase clinical trial rinvoq adult patients active psa results selectpsa study evaluated rinvoq versus placebo patients adequately respond treatment one non biologic diseasemodifying antirheumatic drugs dmards showed doses rinvoq met primary key secondary endpoints safety profile consistent previous studies across indications new safety risks detected may abbvie submitted supplemental new drug application snda us food drug administration fda june submitted marketing authorization application maa european medicines agency ema rinvoq treatment adult patients active psa june abbvie announced topline results phase measure study july announced topline results phase measure ad studies rinvoq treatment moderate severe atopic dermatitis ad met primary secondary endpoints versus placebo august abbvie submitted snda fda earlier year submitted maa ema rinvoq treatment adult patients active ankylosing spondylitis october abbvie submitted snda fda maa ema rinvoq treatment adult adolescent patients moderate severe ad december abbvie announced phase uachieve induction study rinvoq treatment adult patients moderate severe ulcerative colitis met primary ranked secondary endpoints january abbvie announced european commission ec approved rinvoq treatment adults active psa active oncology imbruvica april abbvie received fda approval use imbruvica combination rituximab treatment previously untreated patients chronic lymphocytic leukemia cll small lymphocytic lymphoma sll august ec granted marketing authorization imbruvica combination rituximab treatment adult patients previously untreated cll venclexta february abbvie announced phase vialec trial venclexta combination lowdose cytarabine newlydiagnosed patients acute myeloid leukemia aml meet primary endpoint march abbvie announced topline results phase vialea trial venclexta combination azacitidine patients aml met primary endpoints march abbvie received ec approval venclyxto combination obinutuzumab patients previously untreated cll june abbvie submitted maa ema venclyxto treatment patients aml october abbvie received fda full approval venclexta treatment patients aml approval supported data series trials including phase vialea vialec studies aesthetics juvederm collection june abbvie received fda approval juvederm voluma xc augmentation chin region improve chin profile adults age neuroscience botox therapeutic june fda accepted company 's supplemental biologics license application sbla expand botox prescribing information treatment detrusor bladder muscle overactivity associated underlying neurologic condition certain pediatric patients february abbvie received fda approval botox treatment detrusor overactivity associated neurological condition certain pediatric patients years age older july abbvie received fda approval botox treatment lower limb spasticity caused cerebral palsy pediatric patients age atogepant july abbvie announced phase advance trial evaluating atogepant orally administered calcitonin generelated peptide receptor antagonist migraine prevention met primary endpoint doses mg mg mg compared placebo secondary endpoints mg mg doses four six secondary endpoints mg dose january abbvie submitted new drug application fda atogepant prevention episodic migraine elezanumab september abbvie announced fda granted orphan drug fast track designations elezanumab investigational treatment patients following spinal cord injury form kvirologyliver disease mavyret march abbvie announced ec granted marketing authorization maviret shorten oncedaily treatment duration weeks treatmentnave compensated cirrhotic chronic hepatitis c virus hcv patients genotype infection eye care agn october abbvie announced topline results phase gemini studies agn investigational ophthalmic solution treatment presbyopia met primary endpoint majority secondary endpoints abicipar pegol june abbvie announced fda issued complete response letter crl biologics license application bla abicipar pegol novel investigational darpin therapy patients neovascular wet agerelated macular degeneration namd crl indicated rate intraocular inflammation observed following administration abicipar pegol results unfavorable benefitrisk ratio treatment namd july abbvie withdrew regulatory application ema abicipar pegol treatment namd women 's health oriahnn may fda approved oriahnn elagolix estradiol norethindrone acetate capsules elagolix capsules management heavy menstrual bleeding due uterine fibroids premenopausal women results operations net revenues comparisons presented constant currency rates reflect comparative local currency net revenues prior year 's foreign exchange rates measure provides information change net revenues assuming foreign currency exchange rates changed prior current periods abbvie believes nongaap measure change net revenues constant currency rates used conjunction gaap measure change net revenues actual currency rates may provide complete understanding company 's operations facilitate analysis company 's results operations particularly evaluating performance one period another percent change actual currency rates constant currency rates years ended dollars millions united states international net revenues following table details abbvie 's worldwide net revenues percent change actual currency rates constant currency rates years ended december dollars millions immunology humira united states international total skyrizi united states nm nm international nm nm total nm nm rinvoq united states nm nm international nm nm total nm nm hematologic oncology imbruvica united states collaboration revenues total venclexta united states international total aesthetics botox cosmetic united states nm nm nm nm international nm nm nm nm total nm nm nm nm juvederm collection united states nm nm nm nm international nm nm nm nm total nm nm nm nm aesthetics united states nm nm nm nm international nm nm nm nm total nm nm nm nm neuroscience botox therapeutic united states nm nm nm nm international nm nm nm nm total nm nm nm nm vraylar united states nm nm nm nm duodopa united states international total ubrelvy united states nm nm nm nm neuroscience united states nm nm nm nm international nm nm nm nm total nm nm nm nm form kpercent change actual currency rates constant currency rates years ended december dollars millions eye care lumiganganfort united states nm nm nm nm international nm nm nm nm total nm nm nm nm alphagancombigan united states nm nm nm nm international nm nm nm nm total nm nm nm nm restasis united states nm nm nm nm international nm nm nm nm total nm nm nm nm eye care united states nm nm nm nm international nm nm nm nm total nm nm nm nm women 's health lo loestrin united states nm nm nm nm international nm nm nm nm total nm nm nm nm orilissaoriahnn united states international nm nm total women 's health united states nm nm nm nm international nm nm nm nm total nm nm nm nm key products mavyret united states international total creon united states lupron united states international total linzessconstella united states nm nm nm nm international nm nm nm nm total nm nm nm nm synthroid united states total net revenues nm meaningful net revenues include allergan product revenues date acquisition may december following discussion analysis abbvie 's net revenues product presented constant currency basis global humira sales increased primarily driven market growth across therapeutic categories offset direct biosimilar competition certain international markets united states humira sales increased driven market growth across indications favorable pricing partially offset lower new patient starts due covid pandemic internationally humira revenues decreased primarily driven direct biosimilar competition certain international markets biosimilar competition humira expected united states abbvie continues pursue strategies intended maintain market leadership among installed patient base add sustainability humira net revenues skyrizi increased primarily driven market growth market share gains prior year following april regulatory approvals treatment moderate severe plaque psoriasis net revenues rinvoq increased primarily driven august fda approval december ec approval treatment moderate severe rheumatoid arthritis net revenues imbruvica represent product revenues united states collaboration revenues outside united states related abbvie 's share imbruvica profit abbvie 's global imbruvica revenues increased result continued penetration imbruvica patients cll partially offset lower new patient starts due covid pandemic net revenues venclexta increased primarily due continued expansion venclexta treatment patients firstline cll relapsedrefractory cll firstline aml net revenues botox cosmetic used facial aesthetics billion period subsequent completion allergan acquisition net revenues juvederm collection including juvederm ultra xc juvederm voluma xc juvederm products used facial aesthetics million period subsequent completion allergan acquisition net revenues botox therapeutic used primarily neuroscience urology therapeutic areas billion period subsequent completion allergan acquisition net revenues vraylar treatment schizophrenia bipolar disorder bipolar depression million period subsequent completion allergan acquisition global mavyret sales decreased primarily driven lower global new patient starts due covid pandemic well competitive dynamics us net revenues creon increased primarily driven continued market growth partially offset lower new patient starts due covid pandemic creon maintains market leadership pancreatic enzyme market approximately total market share net revenues lupron decreased primarily due nearterm supply issue impacted product availability certain formulations gross margin percent change years ended december dollars millions gross margin percent net revenues gross margin percentage net revenues decreased primarily due unfavorable impacts higher amortization intangible assets inventory fair value stepup adjustments associated allergan acquisition well collaboration profit sharing arrangements imbruvica venclexta selling general administrative percent change years ended december dollars millions selling general administrative percent net revenues selling general administrative sga expenses percentage net revenues increased primarily due unfavorable impacts incremental sga expenses allergan including transaction integration costs resulting acquisition research development acquired inprocess research development percent change years ended december dollars millions research development percent net revenues acquired inprocess research development research development rd expenses percentage net revenues decreased primarily due billion intangible asset impairment charge represented remaining value iprd acquired part form kof stemcentrx acquisition following decision terminate rovat rd program see note consolidated financial statements additional information regarding impairment charge rd expenses percentage net revenues also favorably impacted increased scale combined company period subsequent completion allergan acquisition acquired iprd expenses reflect upfront payments related various collaborations acquired iprd expense included charge million result entering collaboration agreement genmab genmab research develop commercialize investigational bispecific antibody therapeutics treatment cancer acquired iprd expense also included charge million result collaboration agreement imab biopharma imab development commercialization lemzoparlimab treatment multiple cancers see note consolidated financial statements additional information regarding genmab imab agreements individually significant transactions cash flows operating expenses income operating income included million income legal settlement related intellectual property dispute third party million income related amended restated license agreement abbvie reata see note consolidated financial statements additional information reata agreement nonoperating expenses years ended december millions interest expense interest income interest expense net net foreign exchange loss expense net interest expense increased compared primarily due higher average debt balance associated financing allergan acquisition well incremental allergan debt acquired partially offset favorable impact lower interest rates companys debt obligations interest income decreased compared primarily due lower average cash cash equivalents balance result cash paid allergan acquisition unfavorable impact lower interest rates expense net included charges related change fair value contingent consideration liabilities billion billion fair value contingent consideration liabilities impacted passage time multiple inputs including probability success achieving regulatorycommercial milestones discount rates estimated amount future sales acquired products marketbased factors change fair value primarily included increase skyrizi contingent consideration liability due higher estimated future sales driven stronger market share uptake favorable clinical trial results well lower interest rates skyrizi contingent consideration liability increased due higher probabilities success higher estimated future sales declining interest rates passage time higher probabilities success primarily resulted april regulatory approvals skyrizi treatment moderate severe plaque psoriasis changes partially offset million decrease stemcentrx contingent consideration liability due termination rovat rd program income tax expense effective income tax rate negative negative effective tax rate period differed statutory tax rate principally due impact foreign operations reflects impact lower income tax rates locations outside united states tax incentives puerto rico foreign tax jurisdictions business development activities changes enacted tax rates laws related restructuring cost repatriation decisions tax audit settlements boehringer ingelheim accretion contingent consideration decrease effective tax rate prior year principally due recognition net tax benefit billion related changes tax laws related restructuring including certain intragroup transfers intellectual property deferred tax remeasurement financial position liquidity capital resources years ended december millions cash flows operating activities investing activities financing activities operating cash flows increased included results allergan subsequent may acquisition date operating cash flows favorably impacted higher net revenues combined company timing working capital cash flows partially offset acquisition related cash expenses operating cash flows also reflected abbvies contributions defined benefit plans million million investing cash flows primarily included billion cash consideration paid acquire allergan offset cash acquired billion investing cash flows also included net sales maturities investments totaling billion payments made acquisitions investments billion capital expenditures million investing cash flows included net sales maturities investment securities totaling billion resulting sale substantially company 's investments debt securities payments made acquisitions investments billion capital expenditures million financing cash flows included issuance term loans totaling billion existing billion term loan credit agreement used finance acquisition allergan subsequent borrowings abbvie terminated unused commitments lenders term loan additionally financing cash flows included may repayment billion aggregate principal amount company 's senior notes maturity september repayment million aggregate principal amount allergan exchange notes maturity november repayments million aggregate principal amount floating rate allergan exchange notes maturity million aggregate principal amount allergan exchange notes due february financing cash flows included issuance billion aggregate principal amount floating rate fixed rate unsecured senior notes used finance acquisition allergan additionally financing cash flows included issuance billion aggregate principal amount unsecured senior euro notes company used redeem billion aggregate principal amount senior euro notes due mature november well repayment billion day term loan credit agreement scheduled mature june cash dividend payments totaled billion billion increase cash dividend payments primarily driven higher outstanding shares following million shares abbvie common stock issued allergan shareholders may well increase dividend rate october abbvie announced board directors declared increase quarterly cash dividend per share per share beginning dividend payable february stockholders record january reflects increase approximately previous quarterly rate timing declaration amount payment dividends abbvie future within discretion board directors depend upon many factors including abbvie 's financial condition earnings capital requirements operating subsidiaries covenants associated certain abbvie 's debt service obligations legal requirements regulatory constraints industry practice ability access capital markets factors deemed relevant board directors company 's stock repurchase authorization permits purchases abbvie shares time time openmarket private transactions managements discretion program time limit discontinued time authorization abbvie repurchased million shares million million shares million abbvie cashsettled million december open market purchases january abbvie 's remaining stock repurchase authorization billion december company issued redeemed commercial paper commercial paper borrowings outstanding december december abbvie may issue additional commercial paper retire commercial paper meet liquidity requirements needed credit risk abbvie monitors economic conditions creditworthiness customers government regulations funding domestically abroad abbvie regularly communicates customers regarding status receivable balances including payment plans obtains positive confirmation validity receivables abbvie establishes form kallowance credit losses equal estimate future losses contractual life outstanding accounts receivable abbvie may also utilize factoring arrangements mitigate credit risk although receivables included arrangements historically significant amount total outstanding receivables credit facility access capital credit ratings credit facility abbvie currently billion fiveyear revolving credit facility matures august amended facility enables company borrow funds unsecured basis variable interest rates contains various covenants december company compliance covenants commitment fees credit facility insignificant amounts outstanding company 's credit facility december access capital company intends fund shortterm longterm financial obligations mature cash hand future cash flows operations ability issue additional debt company 's ability generate cash flows operations issue debt enter financing arrangements acceptable terms could adversely affected material decline demand company 's products solvency customers suppliers deterioration company 's key financial ratios credit ratings material unfavorable changes business conditions current time company believes sufficient financial flexibility issue debt enter financing arrangements attract longterm capital acceptable terms support company 's growth objectives credit ratings following acquisition allergan sp global ratings revised ratings outlook stable negative lowered issuer credit rating one notch bbb shortterm rating changes moody 's investor service baa senior unsecured longterm rating prime shortterm rating stable outlook unfavorable changes ratings may adverse impact future financing arrangements however would affect companys ability draw credit facility would result acceleration scheduled maturities companys outstanding debt contractual obligations following table summarizes abbvie 's estimated contractual obligations december less one three millions total one year three years five years five years shortterm borrowings longterm debt including current portion interest longterm debta noncancelable operating finance lease payments purchase obligations otherb longterm liabilities c e total includes estimated future interest payments longterm debt interest payments debt calculated future periods using forecasted interest rates effect end projected interest payments include related effects interest rate swap agreements certain projected interest payments may differ future based changes floating interest rates factors events projected interest payments pertain obligations agreements outstanding december see note consolidated financial statements additional information regarding company 's debt instruments note additional information interest rate swap agreements outstanding december b includes company 's significant unconditional purchase obligations commitments exceed company 's projected requirements made normal course business c excludes liabilities associated company 's unrecognized tax benefits possible reliably estimate timing future cash outflows related liabilities see note consolidated financial statements additional information unrecognized tax benefits includes billion contingent consideration liabilities recorded fair value consolidated balance sheet potential contingent consideration payments exceed fair value recorded consolidated balance sheet included table contractual obligations see note consolidated financial statements additional information regarding liabilities e includes onetime transition tax liability mandatory deemed repatriation previously untaxed earnings foreign subsidiaries resulting us tax reform enacted onetime transition tax generally payable eight annual installments abbvie enters rd collaboration arrangements third parties may require future milestone payments third parties contingent upon achievement certain development regulatory commercial milestones individually arrangements insignificant one annual reporting period however milestones multiple products covered arrangements would happen reached reporting period aggregate charge expense could material results operations period business perspective payments viewed positive signify product successfully moving development generating likely generate future cash flows product sales possible predict reasonable certainty whether milestones achieved timing achievement result potential payments included table contractual obligations see note consolidated financial statements additional information collaboration arrangements critical accounting policies estimates preparation financial statements accordance generally accepted accounting principles united states requires use estimates assumptions affect reported amounts assets liabilities reported amounts revenue expenses summary company 's significant accounting policies included note consolidated financial statements certain policies considered critical significantly impact company 's financial condition results operations require difficult subjective complex judgments often result need make estimates effect matters inherently uncertain actual results may vary estimates revenue recognition abbvie recognizes revenue control promised goods services transferred companys customers amount reflects consideration abbvie expects entitled exchange goods services sales value add taxes collected concurrent revenue producing activities excluded revenue abbvie generates revenue primarily product sales majority sales company transfers control invoices customer recognizes revenue upon shipment customer rebates abbvie provides rebates pharmacy benefit managers state government medicaid programs insurance companies administer medicare drug plans wholesalers group purchasing organizations government agencies private entities rebate chargeback accruals accounted variable consideration recorded reduction revenue period related product sold provisions rebates chargebacks totaled billion billion billion rebate amounts typically based upon volume purchases using contractual statutory prices may vary product payer type rebate factors used calculations accrual rebate include identification products subject rebate applicable price terms estimated lag time sale payment rebate significant order establish rebate chargeback accruals company uses internal external data estimate level inventory distribution channel rebate claims processing lag time type rebate estimate rebate percentage net price company tracks sales product customer payer company evaluates inventory data reported wholesalers available prescription volume information product pricing historical experience factors order determine adequacy reserves abbvie regularly monitors reserves records adjustments rebate trends rebate programs contract terms legislative changes significant events indicate change reserve appropriate historically adjustments rebate accruals material net earnings form kthe following table analysis three largest rebate accruals chargeback allowances comprise approximately total consolidated rebate chargebacks recorded reductions revenues remaining rebate provisions charged gross revenues significant determination operating earnings medicaid managed medicare care wholesaler millions rebates rebates chargebacks balance december provisions payments balance december provisions payments balance december additionsa provisions payments balance december represents rebate accruals chargeback allowances assumed allergan acquisition cash discounts product returns cash discounts product returns totaled billion billion billion accounted variable consideration recorded reduction revenue period related product sold reserve cash discounts readily determinable company 's experience payment history fairly consistent product returns reliably estimated based company 's historical return experience pension postemployment benefits abbvie engages outside actuaries assist determination obligations costs pension postemployment benefit plans direct obligations abbvie valuation funded status net periodic benefit cost plans calculated using actuarial assumptions significant assumptions reviewed annually include discount rate expected longterm rate return plan assets health care cost trend rates disclosed note consolidated financial statements discount rate selected based current market rates highquality fixedincome investments december year abbvie employs yield curve approach countries robust bond market exists yield curve developed using highquality bonds yieldcurve approach reflects plans ' specific cash flows ie duration calculating benefit obligations applying corresponding individual spot rates along yield curve abbvie reflects plans ' specific cash flows applies corresponding individual spot rates along yield curve calculating service cost interest cost portions expense countries abbvie reviews various indices corporate bond government bond benchmarks estimate discount rate abbvie 's assumed discount rates significant effect amounts reported defined benefit pension postemployment plans december basis point change assumed discount rate would following effects abbvie 's calculation net periodic benefit costs projected benefit obligations december basis point millions brackets denote reduction increase decrease defined benefit plans service interest cost projected benefit obligation postemployment plans service interest cost projected benefit obligation expected longterm rate return based asset allocation historical performance current view expected future returns abbvie considers inputs longterm focus avoid shortterm market influences current longterm rate return plan assets plan supported historical performance trust 's actual target asset allocation abbvie 's assumed expected longterm rate return significant effect amounts reported defined benefit pension plans december used calculation net periodic benefit cost one percentage point change assumed expected longterm rate return plan assets would increase decrease net period benefit cost plans million health care cost trend rate selected reviewing historical trends current views projected future health care cost increases current health care cost trend rate supported historical trend experience plan assumed health care cost trend rates significant effect amounts reported health care plans december used calculation net periodic benefit cost income taxes abbvie accounts income taxes asset liability method provisions federal state foreign income taxes calculated reported pretax earnings based current tax laws deferred taxes provided using enacted tax rates future tax consequences temporary differences differences financial statement carrying amount assets liabilities respective tax bases tax benefits carryforwards valuation allowance established maintained based currently available information likely portion deferred tax asset realized litigation company subject contingencies various claims legal proceedings investigations regarding product liability intellectual property commercial securities matters arise normal course business see note consolidated financial statements additional information loss contingency provisions recorded probable losses management 's best estimate loss best estimate made minimum loss contingency amount within probable range recorded accordingly abbvie often initially unable develop best estimate loss therefore minimum amount could zero recorded information becomes known either minimum loss amount increased resulting additional loss provisions best estimate made also resulting additional loss provisions occasionally best estimate amount changed lower amount events result expectation favorable outcome previously expected valuation goodwill intangible assets abbvie acquired may continue acquire significant intangible assets connection business combinations abbvie records fair value transactions involving purchase sale intangible assets occur frequency companies pharmaceuticals industry valuations usually based discounted cash flow analysis incorporating stage completion discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants factors significantly affect value intangible asset iprd acquired business combination capitalized indefinitelived intangible asset regulatory approval obtained time accounted definitelived asset amortized estimated useful life discontinuation point intangible asset written iprd acquired transactions business combinations expensed immediately unless deemed alternative future use payments made third parties subsequent regulatory approval capitalized amortized remaining useful life abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable goodwill indefinitelived intangible assets reviewed impairment annually event occurs could result impairment see note consolidated financial statements information annually company tests goodwill impairment first assessing qualitative factors determine whether likely fair value less carrying amount factors considered assessment include general macroeconomic conditions conditions specific industry market cost factors overall financial performance whether sustained declines company 's share price company concludes likely fair value reporting unit less carrying amount quantitative impairment test performed abbvie tests indefinitelived intangible assets impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value less carrying amount quantitative impairment test performed form kfor quantitative impairment tests company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views use alternative estimates assumptions could increase decrease estimated fair value assets could potentially impact company 's results operations actual results may differ company 's estimates contingent consideration fair value measurements contingent consideration liabilities determined acquisition date based significant unobservable inputs including discount rate estimated probabilities timing achieving specified development regulatory commercial milestones estimated amount future sales acquired products contingent consideration liabilities revalued fair value subsequent reporting date related contingency resolved potential contingent consideration payments estimated applying probabilityweighted expected payment model contingent milestone payments monte carlo simulation model contingent royalty payments discounted present value changes fair value contingent consideration liabilities result changes one number inputs including discount rates probabilities achieving milestones time required achieve milestones estimated future sales significant judgment employed determining appropriateness certain inputs changes inputs described could material impact company 's financial position results operations given period fair value company 's contingent consideration liabilities december calculated using following significant unobservable inputs range weighted averagea discount rate probability payment unachieved milestones probability payment royalties indicationb projected year payments unobservable inputs weighted relative fair value contingent consideration liabilities b excludes early stage indications estimated probability payment includes approved indications probability payment excluding approved indications estimated probability payment ranged december recent accounting pronouncements see note consolidated financial statements additional information recent accounting pronouncements item quantitative qualitative disclosures market risk company exposed risk earnings cash flows equity could adversely impacted changes foreign exchange rates interest rates certain derivative instruments used available costeffective basis hedge company 's underlying economic exposures see note consolidated financial statements additional information regarding company 's financial instruments hedging strategies foreign currency risk abbvie 's primary net foreign currency exposures euro japanese yen canadian dollar british pound following table reflects total foreign currency forward exchange contracts outstanding december weighted fair carrying fair carrying average exchange value weighted average value december millions contract amount rate receivablepayable contract amount exchange rate receivablepayable receive primarily us dollars exchange following currencies euro japanese yen canadian dollar british pound currencies na na total company estimates appreciation underlying currencies hedged levels us dollar variables held constant would decrease fair value foreign exchange forward contracts billion december realized appreciation would negatively affect earnings remaining life contracts however gains losses hedging instruments offset losses gains hedged transactions reduce earnings stockholders ' equity volatility relating foreign exchange appreciation believed reasonably possible nearterm change foreign currencies december company billion aggregate principal amount unsecured senior euro notes outstanding exposed foreign currency risk company designated foreign currency denominated notes hedges net investments certain foreign subsidiaries affiliates result foreign currency translation gains losses related euro notes included accumulated comprehensive loss see note consolidated financial statements additional information regarding senior euro notes note consolidated financial statements additional information regarding net investment hedging program interest rate risk company estimates increase interest rates basis points would adversely impact fair value abbvie 's interest rate swap contracts approximately million december realized fair value reduction would affect earnings remaining life contracts company estimates increase basis points longterm interest rates would decrease fair value longterm debt billion december basis point change believed reasonably possible nearterm change interest rates form kitem financial statements supplementary data consolidated financial statements consolidated statements earnings consolidated statements comprehensive income consolidated balance sheets consolidated statements equity consolidated statements cash flows notes consolidated financial statements report independent registered public accounting firm abbvie inc subsidiaries consolidated statements earnings years ended december millions except per share data net revenues cost products sold selling general administrative research development acquired inprocess research development operating income expense total operating costs expenses operating earnings interest expense net net foreign exchange loss expense net earnings income tax expense income tax expense benefit net earnings net earnings attributable noncontrolling interest net earnings attributable abbvie inc per share data basic earnings per share attributable abbvie inc diluted earnings per share attributable abbvie inc weightedaverage basic shares outstanding weightedaverage diluted shares outstanding accompanying notes integral part consolidated financial statements form kabbvie inc subsidiaries consolidated statements comprehensive income years ended december millions net earnings foreign currency translation adjustments net tax expense benefit net investment hedging activities net tax expense benefit pension postemployment benefits net tax expense benefit marketable security activities net tax expense benefit cash flow hedging activities net tax expense benefit comprehensive income loss comprehensive income comprehensive income attributable noncontrolling interest comprehensive income attributable abbvie inc accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated balance sheets december millions except share data assets current assets cash equivalents shortterm investments accounts receivable net inventories prepaid expenses total current assets investments property equipment net intangible assets net goodwill assets total assets liabilities equity current liabilities shortterm borrowings current portion longterm debt finance lease obligations accounts payable accrued liabilities total current liabilities longterm debt finance lease obligations deferred income taxes longterm liabilities commitments contingencies stockholders equity deficit common stock par value shares authorized shares issued december december common stock held treasury cost shares december december additional paidin capital retained earnings accumulated comprehensive loss total stockholders ' equity deficit noncontrolling interest total equity deficit total liabilities equity accompanying notes integral part consolidated financial statements form kabbvie inc subsidiaries consolidated statements equity common shares common treasury additional retained accumulated noncontrolling years ended december millions outstanding stock stock paidin capital earnings comprehensive loss interest total balance december adoption new accounting standardsa net earnings attributable abbvie inc comprehensive income net tax dividends declared purchases treasury stock stockbased compensation plans balance december net earnings attributable abbvie inc comprehensive loss net tax dividends declared purchases treasury stock stockbased compensation plans balance december net earnings attributable abbvie inc comprehensive income net tax dividends declared common shares equity awards issued acquisition allergan plc purchases treasury stock stockbased compensation plans change noncontrolling interest balance december adoption new accounting standards primarily includes cumulativeeffect adjustment accounting standards update asu income taxes topic intraentity transfers assets inventory accompanying notes integral part consolidated financial statements abbvie inc subsidiaries consolidated statements cash flows years ended december millions brackets denote cash outflows cash flows operating activities net earnings adjustments reconcile net earnings net cash operating activities depreciation amortization intangible assets deferred income taxes change fair value contingent consideration liabilities stockbased compensation upfront costs milestones related collaborations gain divestitures intangible asset impairment impacts related us tax reform net changes operating assets liabilities net acquisitions accounts receivable inventories prepaid expenses assets accounts payable liabilities income tax assets liabilities net cash flows operating activities cash flows investing activities acquisition businesses net cash acquired acquisitions investments acquisitions property equipment purchases investment securities sales maturities investment securities net cash flows investing activities cash flows financing activities net change commercial paper borrowings proceeds issuance shortterm borrowings repayments shortterm borrowings proceeds issuance longterm debt repayments longterm debt finance lease obligations debt issuance costs dividends paid purchases treasury stock proceeds exercise stock options payments contingent consideration liabilities net cash flows financing activities effect exchange rate changes cash equivalents net change cash equivalents cash equivalents beginning year cash equivalents end year supplemental information interest paid net portion capitalized income taxes paid received supplemental schedule noncash investing financing activities issuance common shares associated acquisitions businesses accompanying notes integral part consolidated financial statements form kabbvie inc subsidiaries notes consolidated financial statements note background background principal business abbvie inc abbvie company discovery development manufacture sale broad line pharmaceutical products abbvie 's products generally sold worldwide directly wholesalers distributors government agencies health care facilities specialty pharmacies independent retailers abbvieowned distribution centers public warehouses certain products including aesthetic products devices also sold directly physicians licensed healthcare providers united states abbvie distributes pharmaceutical products principally independent wholesale distributors sales directly retailers pharmacies patients outside united states abbvie sells products primarily customers distributors depending market served abbvie incorporated delaware april january abbvie became independent publiclytraded company result distribution abbott laboratories abbott outstanding common stock abbvie abbott 's shareholders may abbvie completed previously announced acquisition allergan plc allergan refer note additional information regarding acquisition note summary significant accounting policies use estimates consolidated financial statements prepared accordance us generally accepted accounting principles gaap necessarily include amounts based estimates assumptions management actual results could differ amounts significant estimates include amounts rebates pension postemployment benefits income taxes litigation valuation goodwill intangible assets contingent consideration liabilities financial instruments inventory accounts receivable exposures basis consolidation consolidated financial statements include accounts abbvie subsidiaries controlling interest maintained controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities abbvie determined primary beneficiary investments companies abbvie significant influence controlling interest accounted using equity method abbvie 's share earnings losses reported expense net consolidated statements earnings intercompany balances transactions eliminated certain reclassifications made conform prior period consolidated financial statements current period presentation revenue recognition abbvie recognizes revenue control promised goods services transferred companys customers amount reflects consideration abbvie expects entitled exchange goods services sales value add taxes collected concurrent revenue producing activities excluded revenue abbvie generates revenue primarily product sales majority sales company transfers control invoices customer recognizes revenue upon shipment customer company recognizes shipping handling costs expense cost products sold company transfers control customer payment terms vary depending type location customer based customary commercial terms generally less one year abbvie adjust revenue effects significant financing component contracts abbvie expects period transfer good service collection one year less discounts rebates sales incentives customers returns certain adjustments accounted variable consideration provisions variable consideration based current pricing executed contracts government pricing legislation historical data provided period related revenues recorded rebate amounts typically based upon volume purchases using contractual statutory prices may vary product payer type rebate factors used calculation accrual include identification products subject rebate applicable price terms estimated lag time sale payment rebate significant sales incentives customers insignificant addition revenue contracts customers company also recognizes certain collaboration revenues see note additional information related collaborations janssen biotech inc genentech inc additionally see note disaggregation revenue product geography research development expenses internal research development rd costs expensed incurred clinical trial costs incurred third parties expensed contracted work performed contingent milestone payments due third parties research development collaborations prior regulatory approval payment obligations expensed milestone results achieved payments made third parties subsequent regulatory approval capitalized intangible assets amortized cost products sold remaining useful life related product collaborations arrangements company enters collaborative agreements third parties develop commercialize drug candidates collaborative activities may include joint research development commercialization new products abbvie generally receives certain licensing rights arrangements collaborations often require upfront payments may include additional milestone research development cost sharing royalty profit share payments contingent upon occurrence certain future events linked success asset development commercialization upfront payments associated collaborative arrangements development stage expensed acquired inprocess research development iprd expenses consolidated statements earnings subsequent payments made partner achievement milestones development stage expensed rd expense consolidated statements earnings milestone achieved milestone payments made partner subsequent regulatory approval capitalized intangible assets amortized cost products sold estimated useful life related asset royalties expensed cost products sold consolidated statements earnings incurred advertising costs associated advertising expensed incurred included selling general administrative sga expense consolidated statements earnings advertising expenses billion billion billion pension postemployment benefits abbvie records annual expenses relating defined benefit pension postemployment benefit plans based calculations utilize various actuarial assumptions including discount rates rates return assets compensation increases turnover rates health care cost trend rates abbvie reviews actuarial assumptions annual basis makes modifications assumptions based current rates trends actuarial gains losses deferred accumulated comprehensive income loss aoci net tax amortized remaining service attribution periods employees corridor method differences expected longterm return plan assets actual annual return amortized net periodic benefit cost fiveyear period income taxes income taxes accounted asset liability method provisions federal state foreign income taxes calculated reported pretax earnings based current tax laws deferred taxes provided using enacted tax rates future tax consequences temporary differences differences financial statement carrying amounts assets liabilities respective tax bases tax benefits carryforwards valuation allowance established maintained based currently available information likely portion deferred tax asset realized cash equivalents cash equivalents include money market funds time deposits original maturities three months less investments investments consist primarily equity securities heldtomaturity debt securities marketable debt securities time deposits investments equity securities readily determinable fair values recorded fair value investments form kequity securities readily determinable fair values recorded cost remeasured fair value based certain observable price changes impairment events occur heldtomaturity debt securities recorded cost gains losses investments included expense net consolidated statements earnings investments marketable debt securities classified availableforsale recorded fair value unrealized holding gains losses net tax included aoci consolidated balance sheets realized time gains losses recognized earnings abbvie periodically assesses marketable debt securities impairment credit losses decline fair value marketable debt security due credit related factors allowance credit losses recorded corresponding charge expense consolidated statements earnings abbvie determines noncredit related impairment occurred amortized cost basis investment net allowance credit losses written charge expense net consolidated statements earnings availableforsale investment 's unrealized loss reclassified aoci expense net consolidated statements earnings realized gains losses sales investments computed using firstin firstout method adjusted impairments credit losses recorded net earnings accounts receivable accounts receivable stated amortized cost less allowance credit losses allowance credit losses reflects best estimate future losses contractual life outstanding accounts receivable determined basis historical experience specific allowances known troubled accounts currently available information including customer financial condition current forecasted economic conditions inventories inventories valued lower cost firstin firstout basis market cost includes material conversion costs inventories consisted following december millions finished goods workinprocess raw materials inventories property equipment december millions land buildings equipment construction progress property equipment gross less accumulated depreciation property equipment net depreciation property equipment recorded straightline basis estimated useful lives assets estimated useful life buildings ranges years buildings include leasehold improvements amortized life related facility lease including renewal periods appropriate asset whichever shorter estimated useful life equipment ranges years equipment includes certain computer software software development costs incurred connection developing obtaining software internal use amortized years depreciation expense million million million leases shortterm leases term months less recorded balance sheet leases commencing modified later abbvie separate lease components nonlease components company records lease liabilities based present value lease payments lease term abbvie generally uses incremental borrowing rate discount lease liabilities rate implicit lease typically readily determinable certain lease agreements include renewal options company 's control abbvie includes optional renewal periods lease term reasonably certain abbvie exercise option variable lease payments include payments lessors taxes maintenance insurance operating costs well payments adjusted based index rate company 's lease agreements contain significant residual value guarantees restrictive covenants litigation contingencies loss contingency provisions recorded probable liability incurred amount liability reasonably estimated based existing information best estimate made minimum loss contingency amount probable range recorded legal fees expensed incurred abbvie accrues product liability claims undiscounted basis liabilities evaluated quarterly adjusted necessary additional information becomes available receivables insurance recoveries product liability claims recorded assets undiscounted basis probable recovery realized business combinations abbvie utilizes acquisition method accounting business combinations method requires among things results operations acquired companies included abbvie 's results operations beginning respective acquisition dates assets acquired liabilities assumed recognized fair value acquisition date excess fair value consideration transferred fair values net assets acquired recognized goodwill contingent consideration liabilities recognized estimated fair value acquisition date subsequent changes fair value contingent consideration liabilities recognized expense net consolidated statements earnings fair value assets acquired liabilities assumed certain cases may subject revision based final determination fair value period time exceed months acquisition date legal costs due diligence costs business valuation costs business acquisition costs expensed incurred goodwill intangible assets intangible assets acquired business combination recorded fair value using discounted cash flow model discounted cash flow model requires assumptions timing amount future net cash flows risk cost capital terminal values market participants definitelived intangibles amortized estimated useful lives using estimated pattern economic benefit abbvie reviews recoverability definitelived intangible assets whenever events changes circumstances indicate carrying value asset may recoverable abbvie first compares projected undiscounted cash flows generated asset carrying value undiscounted cash flows intangible asset less carrying value intangible asset written fair value cash flows identified individual asset review applied lowest level cash flows largely independent cash flows assets liabilities goodwill indefinitelived assets amortized subject impairment review annually frequently indicators impairment exist impairment goodwill could occur carrying amount reporting unit exceeded fair value reporting unit impairment indefinitelived intangible assets would occur fair value intangible asset less carrying value company tests goodwill impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value reporting unit less carrying amount quantitative impairment test performed abbvie tests indefinitelived intangible assets impairment first assessing qualitative factors determine whether likely fair value less carrying amount company concludes likely fair value less carrying amount quantitative impairment test performed quantitative impairment tests company uses estimated future cash flow approach requires significant judgment respect future volume revenue expense growth rates changes working capital use selection appropriate discount rate asset groupings assumptions estimates estimates assumptions used consistent company 's business plans market participant 's views use alternative estimates assumptions could increase decrease estimated fair value assets potentially result different impacts company 's results operations actual results may differ company 's estimates acquired inprocess research development asset acquisition initial costs rights iprd projects acquired expensed iprd consolidated statements earnings unless project alternative future use costs include initial payments incurred prior form kregulatory approval connection research development collaboration agreements provide rights develop manufacture market andor sell pharmaceutical products business combination fair value iprd projects acquired capitalized accounted indefinitelived intangible assets underlying project receives regulatory approval point intangible asset accounted definitelived intangible asset discontinuation point intangible asset written rd costs incurred acquisition expensed incurred foreign currency translation foreign subsidiary earnings translated us dollars using average exchange rates net assets foreign subsidiaries translated us dollars using periodend exchange rates us dollar effects arise translating net assets subsidiaries changing rates recognized comprehensive income loss oci consolidated statements comprehensive income net assets subsidiaries highly inflationary economies remeasured functional currency reporting currency remeasurement recognized net foreign exchange loss consolidated statements earnings derivatives derivative instruments recognized either assets liabilities fair value consolidated balance sheets classified current longterm based scheduled maturity instrument derivatives formally designated hedges company assesses inception quarterly thereafter whether hedging derivatives highly effective offsetting changes fair value cash flows hedged item changes fair value derivative designated fair value hedge hedged item attributable hedged risk recognized earnings immediately effective portions changes fair value derivative designated cash flow hedge reported aoci subsequently recognized earnings consistent underlying hedged item determined derivative longer highly effective hedge company discontinues hedge accounting prospectively hedged forecasted transaction becomes probable occurring gains losses reclassified aoci earnings derivatives designated hedges adjusted fair value current earnings company also uses derivative instruments foreign currency denominated debt hedge net investments certain foreign subsidiaries affiliates realized unrealized gains losses hedges included aoci derivative cash flows exception net investment hedges principally classified operating section consolidated statements cash flows consistent underlying hedged item cash flows related net investment hedges classified investing section consolidated statements cash flows recent accounting pronouncements recently adopted accounting pronouncements asu june financial accounting standards board fasb issued accounting standards update asu financial instruments credit losses topic standard changes credit losses measured financial assets certain instruments trade receivables heldtomaturity debt securities loans financial instruments standard requires use new forwardlooking expected credit loss model generally result earlier recognition allowances losses availableforsale debt securities unrealized losses standard requires allowances recorded instead reducing amortized cost investment abbvie adopted standard first quarter upon adoption standard accounts receivable stated amortized cost less allowance credit losses allowance credit losses reflects best estimate future losses contractual life outstanding accounts receivable determined basis historical experience specific allowances known troubled accounts currently available information including customer financial condition current forecasted economic conditions adoption material impact company 's consolidated financial statements allowance credit losses million december significant changes credit loss risk factors impacted company 's recorded allowance recent accounting pronouncements yet adopted asu december fasb issued asu income taxes topic standard includes simplifications related accounting income taxes including removing certain exceptions related approach intraperiod tax allocation recognition deferred tax liabilities outside basis differences standard also clarifies accounting transactions result stepup tax basis goodwill standard effective abbvie starting first quarter abbvie completed assessment new standard concluded adoption material impact consolidated financial statements note supplemental financial information interest expense net years ended december millions interest expense interest income interest expense net accounts payable accrued liabilities december millions sales rebates dividends payable accounts payable salaries wages commissions royalty license arrangements accounts payable accrued liabilities longterm liabilities december millions contingent consideration liabilities liabilities unrecognized tax benefits income taxes payable pension postemployment benefits longterm liabilities form knote earnings per share abbvie grants certain restricted stock units rsus considered participating securities due presence participating securities abbvie calculates earnings per share eps using dilutive treasury stock twoclass method periods presented twoclass method dilutive following table summarizes impact twoclass method years ended december millions except per share data basic eps net earnings attributable abbvie inc earnings allocated participating securities earnings available common shareholders weighted average basic shares common stock outstanding basic earnings per share attributable abbvie inc diluted eps net earnings attributable abbvie inc earnings allocated participating securities earnings available common shareholders weighted average shares common stock outstanding effect dilutive securities weighted average diluted shares common stock outstanding diluted earnings per share attributable abbvie inc certain shares issuable stockbased compensation plans excluded computation eps effect would antidilutive number common shares excluded insignificant periods presented note licensing acquisitions arrangements acquisition allergan may abbvie completed previously announced acquisition outstanding equity interests allergan cash stock transaction allergan global pharmaceutical leader focused developing manufacturing commercializing branded pharmaceutical device biologic surgical regenerative medicine products patients around world combination creates diverse entity leadership positions across immunology hematologic oncology aesthetics neuroscience eye care women 's health abbvie 's existing product portfolio pipeline enhanced numerous allergan assets allergan 's product portfolio benefits abbvie 's commercial strength expertise international infrastructure terms acquisition ordinary share allergan common stock converted right receive cash ii share abbvie common stock total consideration acquisition allergan summarized follows millions cash consideration paid allergan shareholders fair value abbvie common stock issued allergan shareholders b fair value abbvie equity awards issued allergan equity award holders c total consideration represents cash consideration transferred per outstanding allergan ordinary share based million allergan ordinary shares outstanding closing b represents acquisition date fair value million shares abbvie common stock issued allergan shareholders based exchange ratio abbvie shares outstanding allergan ordinary share may closing price per share c represents preacquisition service portion fair value million abbvie stock options million rsus issued allergan equity award holders acquisition allergan accounted business combination using acquisition method accounting acquisition method requires among things assets acquired liabilities assumed business combination recognized fair values acquisition date valuation assets acquired liabilities assumed yet finalized december result abbvie recorded preliminary estimates fair value assets acquired liabilities assumed acquisition date subsequent acquisition date company made certain measurement period adjustments preliminary purchase price allocation including increase developed product rights intangible assets billion ii increase iprd intangible assets million iii increase property equipment million iv individually insignificant adjustments net increase identifiable net assets million v corresponding decrease goodwill billion measurement period adjustments primarily resulted revised future cash flow estimates certain intangible assets completing valuations property equipment measurement period adjustments reflected table company made measurement period adjustments reflect facts circumstances existed acquisition date result intervening events subsequent date adjustments significant impact abbvie 's results operations finalization valuation measurement period could result change amounts recorded acquisition date fair value intangible assets goodwill income taxes among items completion valuation occur later one year acquisition date following table summarizes preliminary fair value assets acquired liabilities assumed acquisition date millions assets acquired liabilities assumed cash equivalents shortterm investments accounts receivable inventories prepaid expenses current assets investments property equipment intangible assets developed product rights inprocess research development noncurrent assets shortterm borrowings current portion longterm debt finance lease obligations accounts payable accrued liabilities longterm debt finance lease obligations deferred income taxes longterm liabilities total identifiable net assets goodwill total assets acquired liabilities assumed fair value stepup adjustment inventories billion amortized cost products sold inventory sold customers expected within approximately one year acquisition date intangible assets relate billion developed product rights billion iprd acquired definitelived intangible assets amortized weightedaverage estimated useful life approximately twelve years using estimated pattern economic benefit estimated fair values identifiable intangible assets determined using income approach valuation technique provides estimate fair value asset based market form kparticipant expectations cash flows asset would generate remaining useful life significant assumptions inherent development asset valuations include estimated net cash flows year asset product appropriate discount rate necessary measure risk inherent future cash flow stream life cycle asset potential regulatory commercial success risk competitive trends impacting asset cash flow stream well factors fair value longterm debt determined quoted market prices acquisition date total purchase price adjustment billion amortized reduction interest expense net lives related debt goodwill calculated excess consideration transferred net assets recognized represents future economic benefits arising assets acquired could individually identified separately recognized specifically goodwill recognized acquisition allergan represents value additional growth platforms expanded revenue base well anticipated operational synergies cost savings creation single combined global organization goodwill deductible tax purposes following acquisition date operating results allergan included consolidated financial statements period acquisition date december net revenues attributable allergan billion operating losses attributable allergan billion inclusive billion intangible asset amortization billion inventory fair value stepup amortization acquisitionrelated expenses comprised primarily regulatory financial advisory legal fees totaled million year ended december million year ended december included sga expenses consolidated statements earnings pro forma financial information following table presents unaudited pro forma combined results abbvie allergan acquisition allergan occurred january years ended december millions net revenues net earnings loss unaudited pro forma combined financial information prepared using acquisition method accounting based historical financial information abbvie allergan order reflect occurrence acquisition january required unaudited pro forma financial information includes adjustments reflect incremental amortization expense incurred based current preliminary fair values identifiable intangible assets acquired incremental cost products sold related fair value adjustments associated acquisition date inventory additional interest expense associated issuance debt finance acquisition reclassification acquisitionrelated costs incurred year ended december year ended december unaudited pro forma financial information necessarily indicative consolidated results operations would acquisition completed january addition unaudited pro forma financial information projection future results operations combined company reflect expected realization synergies cost savings associated acquisition licensing acquisitions activity cash outflows related acquisitions investments totaled billion billion million abbvie recorded acquired iprd charges billion million million significant arrangements impacting require contingent milestone payments summarized luminera october abbvie entered agreement luminera privately held aesthetics company based israel acquire luminera 's full dermal filler portfolio rd pipeline including harmonyca dermal filler intended facial soft tissue augmentation aggregate accounting purchase price million comprised million upfront cash payment million acquisition date fair value contingent consideration liabilities abbvie may owe million future payments upon achievement certain commercial milestones harmonyca currently commercially available israel brazil abbvie continue develop product international us markets agreement accounted business combination using acquisition method accounting acquisition date abbvie acquired million intangible assets inprocess research development million intangible assets developed product rights assets liabilities assumed insignificant acquisition resulted recognition million goodwill deductible tax purposes imab biopharma september abbvie imab biopharma imab entered collaboration agreement development commercialization lemzoparlimab anticd monoclonal antibody internally discovered developed imab treatment multiple cancers companies collaborate design conduct global clinical trials evaluate lemzoparlimab collaboration provides abbvie exclusive global license excluding greater china develop commercialize lemzoparlimab companies share manufacturing responsibilities abbvie primary manufacturer global supply agreement also allows potential collaboration future cdrelated therapeutic agents subject licenses explore 's related programs respective territories terms arrangement include initial upfront payment million exclusively license lemzoparlimab along milestone payment million based phase results total million recorded iprd consolidated statements earnings fourth quarter regulatory approval transaction addition imab eligible receive billion upon achievement certain clinical development regulatory commercial milestones abbvie pay tiered royalties lowtomid teen percentages global net revenues outside greater china genmab june abbvie genmab genmab entered collaboration agreement jointly develop commercialize three genmab 's early stage investigational bispecific antibody therapeutics entered discovery research collaboration future differentiated antibody therapeutics treatment cancer terms agreement genmab granted abbvie exclusive license epcoritamab duobodycdxcd duohexabodycd duobodycdxt programs epcoritamab companies share commercial responsibilities us japan abbvie responsible global commercialization genmab record net revenues us japan parties share equally pretax profits sales genmab receive tiered royalties remaining global sales discovery research partnership genmab conduct phase studies programs abbvie retains right optin program development abbvie made upfront payment million recorded iprd consolidated statements earnings abbvie could make additional payments billion upon achievement certain development regulatory commercial milestones programs reata pharmaceuticals inc october abbvie reata pharmaceuticals inc reata entered amended restated license agreement terms agreement reata reacquired exclusive development manufacturing commercialization rights concerning proprietary nrf activator product platform originally licensed abbvie territories outside united states respect bardoxolone methyl worldwide respect omaveloxolone nextgeneration nrf activators consideration rights reacquired reata abbvie received total million december receive million cash total consideration million recognized operating income expense consolidated statements earnings addition abbvie receive low singledigit tiered royalties worldwide sales omaveloxolone certain nextgeneration nrf activators calico life sciences llc june abbvie calico life sciences llc calico entered extension collaboration discover develop bring market new therapies patients agerelated diseases including neurodegeneration cancer terms agreement abbvie calico contribute additional million collaboration term extended additional three years calico responsible research early development advance collaboration projects phase following completion phase abbvie option exclusively license collaboration compounds abbvie support calico early research development efforts upon exercise would responsible latestage development commercial activities collaboration costs profits shared equally parties post option exercise abbvie recorded million operating income expense consolidated statements earnings related commitments agreement arrangements addition significant arrangements described abbvie entered several arrangements resulting charges iprd million million million connection form kindividually insignificant earlystage arrangements entered abbvie could make additional payments billion upon achievement certain development regulatory commercial milestones note collaborations company ongoing transactions entities collaboration agreements following represent significant collaboration agreements impacting collaboration janssen biotech inc december pharmacyclics whollyowned subsidiary abbvie entered worldwide collaboration license agreement janssen biotech inc affiliates janssen one janssen pharmaceutical companies johnson johnson joint development commercialization imbruvica novel orally active selective covalent inhibitor bruton 's tyrosine kinase btk certain compounds structurally related imbruvica oncology indications excluding immune inflammatory mediated diseases conditions psychiatric psychological diseases conditions united states outside united states collaboration provides janssen exclusive license commercialize imbruvica outside united states coexclusively abbvie united states parties responsible development manufacturing marketing products generated result collaboration collaboration set duration specific expiration date provides potential future development regulatory approval milestone payments million abbvie collaboration also includes cost sharing arrangement associated collaboration activities except certain cases janssen responsible approximately collaboration development costs abbvie responsible remaining collaboration development costs united states parties coexclusive rights commercialize products however abbvie principal endcustomer product sales abbvie janssen share pretax profits losses equally commercialization products sales imbruvica included abbvie 's net revenues janssen 's share profits included abbvie 's cost products sold costs incurred collaboration reported respective expense line items net janssen 's share outside united states janssen responsible exclusive rights commercialize imbruvica abbvie janssen share pretax profits losses equally commercialization products abbvie 's share profits included abbvie 's net revenues costs incurred collaboration reported respective expense line items net janssen 's share following table shows profit cost sharing relationship janssen abbvie years ended december millions united states janssen 's share profits included cost products sold international abbvie 's share profits included net revenues global abbvie 's share costs included respective line items abbvies receivable janssen included accounts receivable net million december million december abbvies payable janssen included accounts payable accrued liabilities million december million december collaboration genentech inc abbvie genentech inc genentech member roche group parties collaboration license agreement executed jointly research develop commercialize human therapeutic products containing bcl inhibitors certain compound inhibitors includes venclexta bcl inhibitor used treat certain hematological malignancies abbvie shares equally genentech pretax profits losses development commercialization venclexta united states abbvie pays royalties venclexta net revenues outside united states abbvie manufactures distributes venclexta globally principal endcustomer product sales sales venclexta included abbvie 's net revenues genentech 's share united states profits included abbvie 's cost products sold abbvie records sales marketing costs associated united states collaboration part sga expenses global development costs part rd expenses net genentechs share royalties paid venclexta revenues outside united states also included abbvies cost products sold following table shows profit cost sharing relationship genentech abbvie years ended december millions genentech 's share profits including royalties included cost products sold abbvie 's share sales marketing costs us collaboration included sga abbvie 's share development costs included rd note goodwill intangible assets goodwill following table summarizes changes carrying amount goodwill millions balance december foreign currency translation adjustments balance december additionsa foreign currency translation adjustments balance december goodwill additions related acquisition allergan second quarter acquisition luminera fourth quarter see note company performs annual goodwill impairment assessment third quarter earlier impairment indicators exist december accumulated goodwill impairment losses intangible assets net following table summarizes intangible assets gross net gross net carrying accumulated carrying carrying accumulated carrying december millions amount amortization amount amount amortization amount definitelived intangible assets developed product rights license agreements total definitelived intangible assets indefinitelived research development total intangible assets net definitelived intangible assets increase definitelived intangible assets primarily due acquisition allergan second quarter intangible assets amortized using estimated pattern economic benefit refer note additional information regarding acquisition form kdefinitelived intangible assets amortized estimated useful lives range years average years developed product rights years license agreements amortization expense billion billion billion included cost products sold consolidated statements earnings anticipated annual amortization expense definitelived intangible assets recorded december follows billions anticipated annual amortization expense definitelived intangible asset impairment charges recorded indefinitelived intangible assets indefinitelived intangible assets represent acquired iprd associated products yet received regulatory approval increase indefinitelived research development assets due acquisition allergan second quarter acquisition luminera fourth quarter refer note additional information regarding acquisitions company performs annual impairment assessment indefinitelived intangible assets third quarter earlier impairment indicators exist indefinitelived intangible asset impairment charges recorded following announcement decision terminate rovalpituzumab tesirine rovat rd program company recorded impairment charge billion represented remaining value iprd acquired part stemcentrx acquisition termination subsequent decision stop enrollment tahoe trial resulted impairment charge billion impairment charges recorded rd expense consolidated statements earnings note integration restructuring plans allergan integration plan following closing allergan acquisition abbvie implemented integration plan designed reduce costs integrate optimize combined organization achieve integration objectives abbvie expects incur approximately billion charges costs consist severance employee benefit costs cash severance noncash severance including accelerated equity award compensation expense retention termination benefits integration expenses following table summarizes charges associated allergan acquisition integration plan severance year ended december millions employee benefits integration cost products sold research development selling general administrative total charges following table summarizes cash activity recorded liability associated integration plan severance year ended december millions employee benefits integration charges payments adjustments accrued balance december restructuring abbvie continuously evaluates operations identify opportunities optimize manufacturing rd operations commercial infrastructure administrative costs respond changes business environment result abbvie management periodically approves individual restructuring plans achieve objectives plans individually significant restructuring charges recorded million million million primarily related employee severance contractual obligations charges recorded cost products sold rd expense sga expenses consolidated statements earnings based classification affected employees operations following table summarizes cash activity restructuring reserve millions accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december restructuring charges payments adjustments accrued balance december note leases abbvie 's lease portfolio primarily consists real estate properties vehicles equipment following table summarizes amounts location operating finance leases consolidated balance sheets december millions balance sheet caption assets operating assets finance property equipment net total lease assets liabilities operating current accounts payable accrued liabilities noncurrent longterm liabilities finance current current portion longterm debt finance lease obligations noncurrent longterm debt finance lease obligations total lease liabilities form kthe following table summarizes lease costs recognized consolidated statements earnings years ended december millions operating lease cost shortterm lease cost variable lease cost total lease cost sublease income finance lease costs insignificant lease expense prior adoption asu million following table presents weightedaverage remaining lease term weightedaverage discount rate operating finance leases december december weightedaverage remaining lease term years operating finance weightedaverage discount rate operating finance following table presents supplementary cash flow information regarding company 's leases years ended december millions cash paid amounts included measurement lease liabilities operating cash flows operating leases rightofuse assets obtained exchange new operating lease liabilities finance lease cash flows insignificant rightofuse assets obtained exchange new operating lease liabilities included million rightofuse assets acquired allergan acquisition following table summarizes future maturities abbvie 's operating finance lease liabilities december operating finance millions leases leases total thereafter total lease payments less interest present value lease liabilities lease payments recognized part lease liabilities optional renewal periods insignificant note debt credit facilities commitments contingencies following table summarizes longterm debt effective effective interest rate interest rate december dollars millions senior notes issued notes due notes due senior notes issued notes due notes due notes due notes due notes due senior notes issued notes due notes due notes due notes due notes due senior euro notes issued notes due principal notes due principal senior notes issued notes due notes due notes due notes due senior euro notes issued notes due principal notes due principal senior notes issued floating rate notes due may floating rate notes due november floating rate notes due notes due notes due notes due notes due notes due notes due notes due term loan facilities floating rate notes due floating rate notes due senior notes acquired notes due notes due notes due notes due notes due notes due notes due notes due notes due notes due form keffective effective interest rate interest rate december dollars millions senior euro notes acquired notes due principal notes due principal notes due principal notes due principal notes due principal fair value hedges unamortized bond discounts unamortized deferred financing costs unamortized bond premiums b total longterm debt finance lease obligations current portion noncurrent portion excludes effect related interest rate swaps b represents unamortized purchase price adjustments allergan debt allerganrelated financing connection acquisition allergan may company borrowed billion billion term loan credit agreement billion outstanding floating rate threeyear term loan tranche billion outstanding floating rate fiveyear term loan tranche december subsequent borrowings abbvie terminated unused commitments lenders term loan may abbvie completed previously announced offers exchange outstanding notes certain series issued allergan new notes issued abbvie cash following settlement exchange offers abbvie issued billion billion new notes exchange allergan notes tendered exchange offers aggregate principal amount allergan notes remained outstanding following settlement exchange offers approximately billion million exchange transaction accounted modification assumed debt instruments september company repaid million aggregate principal amount allergan exchange notes maturity november company repaid million aggregate principal amount floating rate allergan exchange notes maturity million aggregate principal amount allergan exchange notes due february three months prior maturity november company issued billion aggregate principal amount unsecured senior notes senior notes rank equally unsecured unsubordinated indebtedness company abbvie may redeem fixedrate senior notes prior maturity redemption price equal greater principal amount sum present values remaining scheduled payments principal interest fixedrate senior notes redeemed plus makewhole premium exception fixedrate notes due abbvie may also redeem fixedrate senior notes par one six months prior maturity connection offering debt issuance costs incurred totaled million debt discounts totaled million amortized respective terms notes interest expense net consolidated statements earnings abbvie used net proceeds fund portion aggregate cash consideration due allergan shareholders connection acquisition described note pay related fees expenses longterm debt may company repaid billion aggregate principal amount senior notes maturity september company issued billion aggregate principal amount unsecured senior euro notes senior notes rank equally unsecured unsubordinated indebtedness company abbvie may redeem senior notes prior maturity redemption price equal principal amount senior notes redeemed plus makewhole premium may redeem senior notes par one three months prior maturity connection offering debt issuance costs incurred totaled million debt discounts totaled million amortized respective terms notes interest expense net consolidated statements earnings october company used proceeds redeem billion aggregate principal amount senior euro notes due mature november may company also repaid billion aggregate principal amount senior notes maturity september company issued billion aggregate principal amount unsecured senior notes senior notes rank equally unsecured unsubordinated indebtedness company abbvie may redeem senior notes prior maturity redemption price equal principal amount senior notes redeemed plus makewhole premium except notes due abbvie may redeem senior notes par one six months prior maturity connection offering debt issuance costs incurred totaled million debt discounts totaled million amortized respective terms senior notes interest expense net consolidated statements earnings billion net proceeds billion used repay company 's outstanding threeyear term loan credit agreement september billion used repay aggregate principal amount senior notes maturity november company used remaining proceeds repay term loan obligations became due abbvie outstanding billion aggregate principal amount unsecured senior euro notes issued abbvie may redeem senior notes prior maturity redemption price equal principal amount senior notes redeemed plus makewhole premium abbvie may redeem senior notes par one three months prior maturity abbvie outstanding billion aggregate principal amount unsecured senior notes issued billion aggregate principal amount unsecured senior notes issued abbvie may redeem senior notes time prior maturity redemption price equal principal amount senior notes redeemed plus makewhole premium abbvie may redeem senior notes par one six months prior maturity abbvie outstanding billion aggregate principal amount unsecured senior notes issued abbvie may redeem senior notes series time senior notes series time time redemption price equal principal amount senior notes redeemed plus makewhole premium december company compliance senior note covenants term loan covenants shortterm borrowings commercial paper borrowings outstanding december december weightedaverage interest rate commercial paper borrowings august abbvie entered amended restated billion fiveyear revolving credit facility matures august amended facility enables company borrow funds unsecured basis variable interest rates contains various covenants company compliance december commitment fees abbvie 's revolving credit facilities insignificant amounts outstanding company 's credit facilities december december march abbvie repaid billion day term loan credit agreement drawn june scheduled mature june form kmaturities longterm debt following table summarizes abbvie 's debt maturities december years ending december millions thereafter total obligations commitments fair value hedges unamortized bond premiums discounts deferred financing costs finance lease obligations total longterm debt finance lease obligations contingencies guarantees connection separation abbvie indemnified abbott liabilities resulting operation abbvie 's business income tax liabilities respect periods prior distribution date liabilities agreed abbvie abbott abbvie material exposures offbalance sheet arrangements specialpurpose entities ordinary course business abbvie periodically entered thirdparty agreements assignment product rights resulted abbvie becoming secondarily liable obligations abbvie previously primarily liable based upon past experience likelihood payments agreements remote note financial instruments fair value measures risk management policy company exposed foreign currency exchange rate interest rate risks related business operations abbvie 's hedging policy attempts manage risks acceptable level based company 's judgment appropriate tradeoff risk opportunity costs company uses derivative nonderivative instruments reduce exposure foreign currency exchange rates abbvie also periodically enters interest rate swaps company agrees exchange specified intervals difference fixed floating interest amounts calculated reference agreed upon notional amount derivative instruments used trading purposes manage exposure changes interest rates investment securities none company 's outstanding derivative instruments contain credit risk related contingent features collateral generally required financial instruments various abbvie foreign subsidiaries enter foreign currency forward exchange contracts manage exposures changes foreign exchange rates anticipated intercompany transactions denominated currency functional currency local entity contracts notional amounts totaling billion december billion december designated cash flow hedges recorded fair value durations forward exchange contracts generally less months accumulated gains losses december reclassified aoci included cost products sold time products sold generally exceeding six months date settlement third quarter company entered treasury rate lock agreements notional amounts totaling billion hedge exposure variability future cash flows resulting changes interest rates related issuance longterm debt connection proposed acquisition allergan treasury rate lock agreements designated cash flow hedges recorded fair value agreements net settled upon issuance senior notes november resulting gain million recognized comprehensive income loss gain reclassified interest expense net lives related debt fourth quarter company entered interest rate swap contracts notional amounts totaling billion december december effect hedge contracts change floatingrate interest obligation fixed rate portion floatingrate debt contracts designated cash flow hedges recorded fair value realized unrealized gains losses included aoci reclassified interest expense net lives floatingrate debt company also enters foreign currency forward exchange contracts manage exposure foreign currency denominated trade payables receivables intercompany loans contracts designated hedges recorded fair value resulting gains losses reflected net foreign exchange loss consolidated statements earnings generally offset losses gains foreign currency exposure managed contracts notional amounts totaling billion december billion december company also uses foreign currency forward exchange contracts foreign currency denominated debt hedge net investments certain foreign subsidiaries affiliates company aggregate principal amount senior euro notes designated net investment hedges billion december billion december addition company foreign currency forward exchange contracts designated net investment hedges notional amounts totaling million december million million chf million december company uses spot method assessing hedge effectiveness derivative instruments designated net investment hedges realized unrealized gains losses hedges included aoci initial fair value hedge components excluded assessment effectiveness recognized interest expense net life hedging instrument abbvie party interest rate swap contracts designated fair value hedges notional amounts totaling billion december billion december effect hedge contracts change fixedrate interest obligation floating rate portion debt abbvie records contracts fair value adjusts carrying amount fixedrate debt offsetting amount amounts excluded assessment effectiveness cash flow hedges fair value hedges following table summarizes amounts location abbvie 's derivative instruments consolidated balance sheets fair value fair value derivatives asset position derivatives liability position december millions balance sheet caption balance sheet caption foreign currency forward exchange contracts accounts payable accrued designated cash flow hedges prepaid expenses liabilities designated cash flow hedges assets longterm liabilities accounts payable accrued designated net investment hedges prepaid expenses liabilities accounts payable accrued designated hedges prepaid expenses liabilities interest rate swap contracts accounts payable accrued designated cash flow hedges prepaid expenses liabilities designated cash flow hedges assets longterm liabilities accounts payable accrued designated fair value hedges prepaid expenses liabilities designated fair value hedges assets longterm liabilities total derivatives certain derivatives subject netting arrangements company 's counterparties company offset derivative assets liabilities within consolidated balance sheets form kthe following table presents pretax amounts gains losses derivative instruments recognized comprehensive income loss years ended december millions foreign currency forward exchange contracts designated cash flow hedges designated net investment hedges interest rate swap contracts designated cash flow hedges treasury rate lock agreements designated cash flow hedges assuming market rates remain constant contract maturities company expects reclassify pretax losses million cost products sold foreign currency cash flow hedges pretax losses million interest expense net interest rate swap cash flow hedges pretax gains million interest expense net treasury rate lock agreement cash flow hedges next months related abbvies nonderivative foreign currency denominated debt designated net investment hedges company recognized comprehensive income loss pretax losses million pretax gains million pretax gains million following table summarizes pretax amounts location derivative instrument net gains losses recognized consolidated statements earnings including net gains losses reclassified aoci net earnings see note amount net gains losses reclassified aoci years ended december millions statement earnings caption foreign currency forward exchange contracts designated cash flow hedges cost products sold designated net investment hedges interest expense net designated hedges net foreign exchange loss treasury rate lock agreements designated cash flow hedges interest expense net interest rate swap contracts designated cash flow hedges interest expense net designated fair value hedges interest expense net debt designated hedged item fair value hedges interest expense net fair value measures fair value hierarchy consists following three levels level valuations based unadjusted quoted prices active markets identical assets company ability access level valuations based quoted prices similar instruments active markets quoted prices identical similar instruments markets active modelbased valuations significant inputs observable market level valuations using significant inputs unobservable market include use judgment company 's management assumptions market participants would use pricing asset liability following table summarizes bases used measure certain assets liabilities carried fair value recurring basis consolidated balance sheet december basis fair value measurement quoted prices significant active markets observable significant identical assets inputs unobservable inputs millions total level level level assets cash equivalents money market funds time deposits debt securities equity securities interest rate swap contracts foreign currency contracts total assets liabilities interest rate swap contracts foreign currency contracts contingent consideration total liabilities following table summarizes bases used measure certain assets liabilities carried fair value recurring basis consolidated balance sheet december basis fair value measurement quoted prices significant active markets observable significant identical assets inputs unobservable inputs millions total level level level assets cash equivalents debt securities equity securities interest rate swap contracts foreign currency contracts total assets liabilities interest rate swap contracts foreign currency contracts contingent consideration total liabilities equity securities consist investments fair values determined using published market price per unit multiplied number units held without consideration transaction costs derivatives entered company valued using observable market inputs including published interest rate curves forward spot prices foreign currencies fair value measurements contingent consideration liabilities determined based significant unobservable inputs including discount rate estimated probabilities timing achieving specified development regulatory commercial milestones estimated amount future sales acquired products potential contingent consideration payments estimated applying probabilityweighted expected payment model contingent milestone payments monte carlo simulation model contingent royalty payments discounted present value changes fair value contingent consideration liabilities result changes one number inputs including discount rates probabilities achieving milestones time required achieve milestones form kand estimated future sales significant judgment employed determining appropriateness certain inputs changes inputs described could material impact company 's financial position results operations given period fair value company 's contingent consideration liabilities december calculated using following significant unobservable inputs range weighted averagea discount rate probability payment unachieved milestones probability payment royalties indicationb projected year payments unobservable inputs weighted relative fair value contingent consideration liabilities b excludes early stage indications estimated probability payment includes approved indications probability payment excluding approved indications estimated probability payment ranged december transfers assets liabilities level fair value hierarchy following table presents changes fair value contingent consideration liabilities measured using level inputs years ended december millions beginning balance additionsa change fair value recognized net earnings payments ending balance additions year ended december represent contingent consideration liabilities assumed allergan acquisition well contingent consideration resulting luminera acquisition change fair value recognized net earnings recorded expense net consolidated statements earnings fourth quarter company recorded billion increase skyrizi contingent consideration liability due higher estimated future sales driven stronger market share uptake favorable clinical trial results well lower interest rates second quarter company recorded billion increase skyrizi contingent consideration liability due higher probabilities success higher estimated future sales declining interest rates higher probabilities success resulted april regulatory approvals skyrizi treatment moderate severe plaque psoriasis third quarter company recorded million decrease stemcentrx contingent consideration liability due termination rovat rd program fourth quarter company recorded million decrease stemcentrx contingent consideration liability due reduction probabilities success achieving regulatory approval certain financial instruments carried historical cost basis fair value book values approximate fair values bases used measure approximate fair values certain financial instruments december shown table basis fair value measurement quoted prices active markets significant significant approximate fair identical assets observable inputs unobservable inputs millions book value values level level level liabilities shortterm borrowings current portion longterm debt finance lease obligations excluding fair value hedges longterm debt finance lease obligations excluding fair value hedges total liabilities book values approximate fair values bases used measure approximate fair values certain financial instruments december shown table basis fair value measurement quoted prices active markets significant significant approximate fair identical assets observable inputs unobservable inputs millions book value values level level level liabilities current portion longterm debt finance lease obligations excluding fair value hedges longterm debt finance lease obligations excluding fair value hedges total liabilities abbvie also holds investments equity securities readily determinable fair values company records investments cost remeasures fair value based certain observable price changes impairment events occur carrying amount investments million december million december significant cumulative upward downward adjustments recorded investments december concentrations risk total net accounts receivable three us wholesalers accounted december december substantially abbvie 's net revenues united states three wholesalers humira adalimumab abbvie 's single largest product accounted approximately abbvie 's total net revenues form knote postemployment benefits abbvie sponsors various pension postemployment benefit plans including defined benefit defined contribution termination indemnity plans cover employees worldwide addition abbvie provides medical benefits primarily eligible retirees united states puerto rico postretirement benefit plans net obligations plans reflected consolidated balance sheets december following table summarizes benefit plan information global abbviesponsored defined benefit postemployment plans defined benefit plans postemployment plans years ended december millions projected benefit obligations beginning period service cost interest cost employee contributions amendments actuarial loss benefits paid acquisition primarily foreign currency translation adjustments end period fair value plan assets beginning period actual return plan assets company contributions employee contributions benefits paid acquisition primarily foreign currency translation adjustments end period funded status end period amounts recognized consolidated balance sheets assets accounts payable accrued liabilities longterm liabilities net obligation actuarial loss net prior service cost credit accumulated comprehensive loss projected benefit obligations pbo table included billion december billion december related international defined benefit plans plans reflected table accumulated benefit obligations abo billion december billion december information pension plans accumulated benefit obligation excess plan assets december millions accumulated benefit obligation fair value plan assets information pension plans projected benefit obligation excess plan assets december millions projected benefit obligation fair value plan assets actuarial losses billion qualified pension plans million postemployment plans primarily driven decrease assumed discount rate actuarial losses billion qualified pension plans million post employment plans primarily driven decrease assumed discount rate change abbvie 's us retiree health benefit plan approved communicated employees retirees october beginning medicareeligible retirees medicareeligible dependents choose health care coverage insurance providers private medicare exchange abbvie continue provide financial support medicareeligible retirees change decreased abbvie 's postemployment benefit obligation increased abbvie 's unrecognized prior service credit december million connection allergan acquisition abbvie assumed certain postemployment benefit obligations recorded fair value upon acquisition second quarter excess projected benefit obligations plan assets recognized liability totaling million amounts recognized comprehensive income loss following table summarizes pretax losses gains included comprehensive income loss years ended december millions defined benefit plans actuarial loss amortization prior service cost amortization actuarial loss foreign exchange loss gain total loss postemployment plans actuarial loss gain prior service cost credit amortization prior service credit amortization actuarial loss total loss gain form knet periodic benefit cost years ended december millions defined benefit plans service cost interest cost expected return plan assets amortization prior service cost amortization actuarial loss net periodic benefit cost postemployment plans service cost interest cost amortization prior service credit amortization actuarial loss net periodic benefit cost components net periodic benefit cost service cost included expense net consolidated statements earnings weightedaverage assumptions used determining benefit obligations measurement date december defined benefit plans discount rate rate compensation increases cash balance interest crediting rate postemployment plans discount rate assumptions used calculating december measurement date benefit obligations used calculation net periodic benefit cost weightedaverage assumptions used determining net periodic benefit cost years ended december defined benefit plans discount rate determining service cost discount rate determining interest cost expected longterm rate return plan assets expected rate change compensation cash balance interest crediting rate postemployment plans discount rate determining service cost discount rate determining interest cost december postretirement health care obligations remeasurement company assumed pre post annual rate increase per capita cost covered health care benefits rate assumed decrease gradually remain level thereafter purposes measuring postretirement health care costs company assumed pre post annual rate increase per capita cost covered health care benefits rate assumed decrease gradually remain level thereafter defined benefit pension plan assets basis fair value measurement quoted prices active markets significant significant unobservable identical assets observable inputs inputs december millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real assets otherf total total assets measured nav fair value plan assets basis fair value measurement quoted prices active markets significant significant unobservable identical assets observable inputs inputs december millions level level level equities us large capa us mid capb internationalc fixed income securities us government securitiesd corporate debt instrumentsd nonus government securitiesd otherd absolute return fundse real assets otherf total total assets measured nav fair value plan assets mix index funds actively managed equity accounts benchmarked various large cap indices b mix index funds actively managed equity accounts benchmarked various mid cap indices c mix index funds actively managed equity accounts benchmarked various nonus equity indices developed emerging markets securities held actively managed accounts index funds mutual funds e primarily funds global mandates flexibility allocate capital broadly across wide range asset classes strategies including limited equities fixed income commodities financial futures currencies securities objectives outperform agreed upon benchmarks specific return volatility targets f investments cash cash equivalents equities registered investment companies quoted prices valued published market prices fixed income securities valued using significant observable inputs quoted prices obtained independent financial service industryrecognized vendors investments held pooled investment funds common collective trusts limited partnerships valued net asset value nav practical expedient estimate fair value nav provided fund administrator based value underlying assets owned fund minus liabilities investment mix equity securities fixed income asset allocation strategies based upon achieving desired return balancing higher return volatile equity securities lower return less volatile fixed income securities investment allocations established plan generally made across range markets industry sectors capitalization sizes case fixed income securities maturities credit quality target investment allocation abbvie pension plan equity securities fixed income securities asset allocation strategies holdings known significant concentrations risk plan assets abbvie pension plan plans expected return plan assets assumption plan based management 's expectations longterm average rates return achieved underlying investment portfolio establishing assumption management considers historical expected returns asset classes plans invested well current economic capital market conditions expected benefit payments following table summarizes total benefit payments expected paid plan participants including payments funded plan company assets defined years ending december millions benefit plans postemployment plans defined contribution plan abbvie 's principal defined contribution plans abbvie savings plan allergan savings plan abbvie recorded expense million million million related plans abbvie provides certain postemployment benefits primarily salary continuation arrangements qualifying employees accrues related cost service lives employees note equity stockbased compensation abbvie grants stockbased awards eligible employees pursuant abbvie incentive stock program isp provides several different forms benefits including nonqualified stock options rsus various performancebased awards isp million shares abbvie common stock reserved issuance awards abbvie employees isp also facilitated assumption certain awards granted abbotts incentive stock program adjusted converted abbott abbvie stockbased awards result abbvie 's separation abbott abbvie measures compensation expense stockbased awards based grant date fair value awards estimated number awards expected vest forfeitures estimated based historical experience time grant revised subsequent periods actual forfeitures differ estimates compensation cost stockbased awards amortized service period could shorter vesting period employee retirement eligible retirement eligible employees generally age older least years service stockbased compensation expense principally related awards issued pursuant isp summarized follows years ended december millions cost products sold research development selling general administrative pretax compensation expense tax benefit aftertax compensation expense realized excess tax benefits associated stockbased compensation totaled million million million stock options stock options awarded employees typically contractual term years generally vest onethird increments threeyear period exercise price equal least market value date grant fair value determined using blackscholes model weighted average grantdate fair values stock options granted connection allergan acquisition second quarter abbvie issued million stock options holders allergan options result conversion options options fairvalued using lattice valuation model refer note additional information regarding allergan acquisition following table summarizes abbvie stock option activity weightedaverage weighted average remaining aggregate intrinsic options thousands aggregate intrinsic value millions options exercise price life years value outstanding december granted granted acquisition exercised lapsed outstanding december exercisable december total intrinsic value options exercised million million million total fair value options vested million december million unrecognized compensation cost related stock options expected recognized expense approximately next two years rsus performance shares rsus awarded employees senior executives key employees generally vest ratable increments three fouryear period recipients rsus entitled receive dividend equivalents dividends declared paid rsu vesting period majority equity awards abbvie grants senior executives key employees performancebased equity awards granted senior executives key employees consist combination performancevested rsus performance shares well nonqualified stock options described performancevested rsus potential vest onethird increments threeyear performance period awards granted performance based abbvie 's return invested capital roic relative defined peer group pharmaceutical biotech life science companies awards granted tranches tied performance based abbvies return equity roe relative defined peer group pharmaceutical biotech life sciences companies recipient may receive one share abbvie common stock vested award performance shares potential vest form kover threeyear performance period may earned based abbvies eps achievement abbvies total stockholder return tsr market condition relative defined peer group pharmaceutical biotech life sciences companies dividend equivalents performancevested rsus performance shares accrue performance period payable vesting extent shares earned weightedaverage grantdate fair value rsus performance shares generally determined based number sharesunits granted quoted price abbvies common stock date grant weightedaverage grantdate fair values performance shares tsr market condition determined using monte carlo simulation model following table summarizes abbvie rsu performance share activity weightedaverage grant share units thousands share units date fair value outstanding december granted granted acquisition vested forfeited outstanding december fair market value rsus performance shares applicable vested million million million connection allergan acquisition second quarter abbvie issued million rsus holders allergan equity awards based conversion factor described transaction agreement refer note additional information regarding allergan acquisition december million unrecognized compensation cost related rsus performance shares expected recognized expense approximately next two years cash dividends cash dividends declared per common share totaled following table summarizes quarterly cash dividends declared dividend per dividend per dividend per date declared payment date share date declared payment date share date declared payment date share stock repurchase program company 's stock repurchase authorization permits purchases abbvie shares time time openmarket private transactions managements discretion program time limit discontinued time shares repurchased programs recorded acquisition cost including related expenses available general corporate purposes abbvie repurchased million shares million million shares million abbvie 's remaining stock repurchase authorization billion december february abbvie 's board directors authorized new billion stock repurchase program superseded abbvie 's previous stock repurchase program december abbvie 's board directors authorized billion increase existing billion stock repurchase program authorization abbvie repurchased approximately million shares billion previous stock repurchase programs abbvie made openmarket share repurchases approximately million shares billion accumulated comprehensive loss following table summarizes changes component accumulated comprehensive loss net tax pension foreign currency net investment post cash flow translation hedging employment marketable hedging millions brackets denote losses adjustments activities benefits security activities activities total balance december comprehensive income loss reclassifications net losses reclassified accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss reclassifications net losses gains reclassified accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss reclassifications net losses gains reclassified accumulated comprehensive loss net currentperiod comprehensive income loss balance december comprehensive income loss included foreign currency translation adjustments totaling gains billion principally due impact strengthening euro translation companys eurodenominated assets comprehensive income loss included foreign currency translation adjustments totaling losses million million principally due impact weakening euro translation companys eurodenominated assets comprehensive loss included pension postemployment benefit plan losses billion primarily due actuarial loss driven lower discount rates see note additional information form kthe table presents impact abbvie 's consolidated statements earnings significant amounts reclassified component accumulated comprehensive loss years ended december millions brackets denote gains net investment hedging activities gains derivative amount excluded effectiveness testinga tax expense total reclassifications net tax pension postemployment benefits amortization actuarial losses otherb tax benefit total reclassifications net tax cash flow hedging activities losses gains foreign currency forward exchange contractsc gains treasury rate lock agreementsa losses gains interest rate swap contractsa tax expense benefit total reclassifications net tax amounts included interest expense net see note b amounts included computation net periodic benefit cost see note c amounts included cost products sold see note addition common stock abbvie 's authorized capital includes million shares preferred stock par value december shares preferred stock issued outstanding note income taxes earnings income tax expense years ended december millions domestic foreign total earnings income tax expense income tax expense years ended december millions current domestic foreign total current taxes deferred domestic foreign total deferred taxes total income tax expense benefit effective tax rate reconciliation years ended december statutory tax rate effect foreign operations us tax credits impacts related us tax reform nondeductible expenses tax law changes related restructuring stockbased compensation excess tax benefit tax audit settlements net effective tax rate effective income tax rate fluctuates year year due allocation company 's taxable earnings among jurisdictions well certain discrete factors events year including changes tax law acquisitions collaborations effective income tax rates differed statutory tax rate principally due impact foreign operations reflects impact lower income tax rates locations outside united states tax incentives puerto rico foreign tax jurisdictions business development activities changes enacted tax rates laws related restructuring cost repatriation decisions tax audit settlements boehringer ingelheim accretion contingent consideration effective income tax rate included recognition net tax benefit billion related changes tax laws related restructuring including certain intragroup transfers intellectual property deferred tax remeasurement effective tax rates periods also reflected benefit us tax credits principally related research development credits orphan drug tax credit puerto rico excise tax credits puerto rico excise tax credits relate legislation enacted puerto rico assesses excise tax certain products manufactured puerto rico tax levied gross inventory purchases entities puerto rico included cost products sold consolidated statements earnings majority tax creditable us income tax purposes effective income tax rate included impacts related us tax reform tax cuts jobs act act signed law december resulting significant changes us corporate tax system including onetime transition tax mandatory deemed repatriation earnings certain foreign subsidiaries previously untaxed act also created minimum tax certain foreign sourced earnings companys accounting policy minimum tax foreign sourced earnings report tax effects basis minimum tax recognized tax expense year incurred period expense favorable impact effective date provisions act related earnings certain foreign subsidiaries impact act affected full year earnings subsidiaries resulting additional tax expense compared previous year effective income tax rates also included effects stemcentrx impairment related expenses form kdeferred tax assets liabilities december millions deferred tax assets compensation employee benefits accruals reserves chargebacks rebates advance payments net operating losses credit carryforwards total deferred tax assets valuation allowances total net deferred tax assets deferred tax liabilities excess book basis tax basis intangible assets excess book basis tax basis investments total deferred tax liabilities net deferred tax liabilities increases deferred tax liabilities primarily due acquisition allergan company recorded excess book basis tax basis intangible assets increases deferred tax assets primarily due deferred tax asset recognition related intragroup transfer intellectual property december company us federal state credit carryforwards million well us federal state nonus net operating loss carryforwards billion expire various times remaining us federal nonus loss carryforwards billion expiration company valuation allowances billion december million december principally related foreign state net operating losses credit carryforwards expected realized act significantly changed timing manner earnings foreign subsidiaries subject us tax therefore unremitted foreign earnings previously considered indefinitely reinvested subject acts transition tax longer considered indefinitely reinvested post earnings subject us minimum tax foreign sourced earnings eligible percent foreign dividends received deduction also considered indefinitely reinvested earnings however company generally considers instances outside basis differences foreign subsidiaries would incur additional us tax upon reversal eg capital gain distribution permanent duration unrecognized tax liability practicable determine unrecognized tax benefits years ended december millions beginning balance increase due acquisition increase due current year tax positions increase due prior year tax positions decrease due prior year tax positions settlements lapse statutes limitations ending balance abbvie abbott entered tax sharing agreement effective date separation provides abbott liable indemnified abbvie income tax liabilities periods prior separation abbvie responsible unrecognized tax benefits related interest penalties periods separation instances existing entity transferred abbvie upon separation recognized net amount potential tax benefits would impact company 's effective tax rate billion billion unrecognized tax benefits recorded table december abbvie would indemnified approximately million increase due current year tax positions increase due prior year tax positions table include amounts related federal state international tax items increase due acquisition table includes amounts related federal state international tax items recorded acquisition accounting related allergan acquisition abbvie recognizes interest penalties related income tax matters income tax expense consolidated statements earnings abbvie recognized gross income tax expense million million million interest penalties related income tax matters abbvie accrual payment gross interest penalties million december million december million december company routinely audited tax authorities significant jurisdictions number audits currently underway reasonably possible next months uncertain tax positions may settled could result decrease gross amount unrecognized tax benefits due potential resolution federal state foreign examinations expiration various statutes limitation company 's gross unrecognized tax benefits balance may change within next months million significant federal state local international matters concluded years company believes adequate provision made income tax uncertainties note legal proceedings contingencies abbvie subject contingencies various claims legal proceedings investigations regarding product liability intellectual property commercial securities matters arise normal course business significant matters described loss contingency provisions recorded probable losses managements best estimate loss best estimate made minimum loss contingency amount within probable range recorded recorded accrual balance litigation approximately million december approximately million december initiation new legal proceedings change status existing proceedings may result change estimated loss accrued abbvie addition operating income included million income legal settlement related intellectual property dispute third party feasible predict outcome proceedings exposures certainty management believes ultimate disposition material adverse effect abbvies consolidated financial position results operations cash flows subject certain exceptions specified separation agreement abbott abbvie abbvie assumed liability control pending threatened legal matters related business including liabilities claims legal proceedings related products part business discontinued prior distribution well assumed retained liabilities indemnify abbott liability arising resulting assumed legal matters antitrust litigation lawsuits pending abbvie others generally alleging patent litigation settlement involving niaspan entered kos pharmaceuticals inc company acquired abbott presently subsidiary abbvie generic company violates federal state antitrust laws state unfair deceptive trade practices unjust enrichment laws plaintiffs generally seek monetary damages andor injunctive relief attorneys ' fees lawsuits pending federal court consist four individual plaintiff lawsuits two consolidated purported class actions one brought niaspan direct purchasers one brought niaspan endpayers cases pending united states district court eastern district pennsylvania coordinated consolidated pretrial proceedings mdl rules niaspan antitrust litigation mdl august court certified class direct purchasers niaspan june court denied endpayers ' motion certify class october orange county california district attorneys office filed lawsuit behalf state california regarding niaspan patent litigation settlement orange county superior court asserting claim unfair competition provision california business professions code seeking injunctive relief restitution civil penalties attorneys fees form kin september federal trade commission ftc filed lawsuit ftc v abbvie inc et al abbvie others united states district court eastern district pennsylvania alleging patent litigation two generic companies regarding androgel sham litigation settlements litigation violated federal antitrust law may court dismissed ftcs settlementrelated claim june following bench trial court found ftc sham litigation claim ordered disgorgement remedy million plus prejudgment interest court denied ftcs request injunctive relief september united states court appeals third circuit reversed district courts finding sham litigation respect one generic company affirmed respect held ftc lacked authority obtain disgorgement remedy vacated district courts award third circuit also affirmed district courts denial ftcs injunction request reinstated ftcs settlement related claim proceedings district court august direct purchasers androgel filed lawsuit king drug co florence inc et al v abbvie inc et al abbvie others united states district court eastern district pennsylvania alleging patent litigation settlements related agreements solvay pharmaceuticals inc company abbott acquired february known abbvie products llc three generic companies violated federal antitrust law also making allegations similar ftc v abbvie inc may perrigo company related entities filed lawsuit abbvie others united states district court eastern district pennsylvania making sham litigation allegations similar ftc v abbvie inc october perrigo lawsuit transferred united states district court new jersey march may putative class action lawsuits filed united states district court northern district illinois indirect humira purchasers alleging abbvies settlements biosimilar manufacturers abbvies humira patent portfolio violated state federal antitrust laws court consolidated lawsuits humira adalimumab antitrust litigation june court dismissed consolidated litigation prejudice plaintiffs appealed dismissal lawsuits pending forest laboratories llc others generally alleging patent litigation settlements involving namenda entered forest generic companies conduct forest involving namenda violated state antitrust unfair deceptive trade practices unjust enrichment laws plaintiffs generally seek monetary damages injunctive relief attorneys fees lawsuits purported class actions filed indirect purchasers namenda consolidated namenda indirect purchaser antitrust litigation united states district court southern district new york lawsuits pending allergan inc generally alleging allergans petitioning us patent office food drug administration conduct allergan involving restasis violated federal state antitrust laws state unfair deceptive trade practices unjust enrichment laws plaintiffs generally seek monetary damages injunctive relief attorneys fees lawsuits certified class action filed behalf indirect purchasers restasis consolidated pretrial purposes united states district court eastern district new york mdl rules restasis cyclosporine ophthalmic emulsion antitrust litigation mdl lawsuits pending forest laboratories llc others generally alleging patent litigation settlements involving bystolic six generic manufacturers violated federal state antitrust laws state unfair deceptive trade practices unjust enrichment laws plaintiffs generally seek monetary damages injunctive relief attorneys fees lawsuits purported class actions filed behalf direct indirect purchasers bystolic consolidated bystolic antitrust litigation united states district court southern district new york government proceedings lawsuits pending allergan several manufacturers generally alleging improperly promoted sold prescription opioid products approximately matters pending allergan federal court cases consolidated pretrial purposes united states district court northern district ohio mdl rules national prescription opiate litigation mdl approximately claims pending various state courts plaintiffs cases include states counties cities native american tribes generally seek compensatory damages july new mexico attorney general filed lawsuit state new mexico ex rel balderas v abbvie inc et al new mexico district court santa fe county abbvie companies alleging marketing androgel violated new mexicos unfair practices act october state added claim new mexico false advertising act shareholder securities litigation june lawsuit elliott associates lp et al v abbvie inc filed five investment funds abbvie cook county illinois circuit court alleging abbvie made misrepresentations omissions connection proposed transaction shire similar lawsuits filed july october abbvie instances chief executive officer court additional investment funds court granted motions dismissing claims three investmentfund plaintiffs appealing one plaintiffs refiled lawsuit new york state court june appeal dismissal illinois pending november new york supreme court county new york dismissed lawsuit plaintiffs seek compensatory punitive damages october federal securities lawsuit holwill v abbvie inc et al filed united states district court northern district illinois abbvie chief executive officer former chief financial officer alleging reasons stated humira sales growth financial filings misleading omitted alleged misconduct connection humira patient reimbursement support services services items value allegedly induced humira prescriptions february shareholder derivative lawsuit elfers v gonzalez et al filed united states district court district delaware alleging certain abbvie directors officers breached fiduciary duties regarding alleged misconduct connection humira patient reimbursement support services services items value connection announcements results abbvies dutch auction tender offer december court dismissed lawsuit lawsuits pending allergan certain current former officers alleging made misrepresentations omissions regarding allergan 's textured breast implants lawsuits filed allergan shareholders consolidated united states district court southern district new york allergan plc securities litigation plaintiffs generally seek compensatory damages attorneys fees september court partially granted allergan 's motion dismiss september court denied plaintiffs class certification motion found lead plaintiff inadequate representative proposed class allowed another putative class member propose new lead plaintiff december court appointed new lead plaintiff lawsuits pending allergan certain current former officers alleging made misrepresentations omissions regarding allergans former actavis generics unit alleged anticompetitive conduct generic drug companies lawsuits filed allergan shareholders consist three purported class actions one individual action consolidated us district court district new jersey allergan generic drug pricing securities litigation another individual action new jersey state court dismissed september plaintiffs seek monetary damages attorneys fees product liability general litigation product liability cases pending plaintiffs generally allege abbvie adequately warn risk certain injuries primarily various birth defects arising use depakote approximately cases pending united states district court southern district illinois along one pending state court plaintiffs generally seek compensatory punitive damages approximately ninetyeight percent pending cases plus unfiled claims subject confidential settlement agreements agreementsinprinciple expected dismissed prejudice qui tam lawsuit us ex rel silbersher v allergan inc et al filed united states district court northern district california several allergan entities others alleging conduct us patent office resulted false claims payment made federal state healthcare payors namenda xr namzaric plaintiffrelator seeks damages attorneys ' fees federal false claims act state law analogues federal government state governments declined intervene lawsuit intellectual property litigation pharmacyclics llc wholly owned subsidiary abbvie seeking enforce patent rights relating ibrutinib capsules drug pharmacyclics sells trademark imbruvica february lawsuit filed united states district court district delaware sandoz inc lek pharmaceuticals dd case pharmacyclics alleges defendants ' proposed generic ibrutinib product infringes certain pharmacyclics patents seeks declaratory injunctive relief janssen biotech inc global collaboration pharmacyclics concerning development marketing imbruvica coplaintiff suit pharmacyclics llc wholly owned subsidiary abbvie seeking enforce patent rights relating ibrutinib tablets drug pharmacyclics sells trademark imbruvica cases filed united states district court form kdistrict delaware march march alvogen pine brook llc natco pharma ltd april zydus worldwide dmcc cadila healthcare limited case pharmacyclics alleges defendants proposed generic ibrutinib tablet product infringes certain pharmacyclics patents seeks declaratory injunctive relief janssen biotech inc global collaboration pharmacyclics concerning development marketing imbruvica coplaintiff suits allergan usa inc allergan sales llc forest laboratories holdings limited wholly owned subsidiaries abbvie seeking enforce patent rights relating cariprazine drug sold trademark vraylar litigation filed united states district court district delaware december sun pharmaceutical industries limited sun pharma global fze aurobindo pharma limited aurobindo pharma usa inc zydus pharmaceuticals usa inc cadila healthcare limited allergan alleges defendants ' proposed generic cariprazine products infringe certain patents seeks declaratory injunctive relief gedeon richter plc inc global collaboration allergan concerning development marketing vraylar coplaintiff suit january allergan inc allergan plc allergan limited medytox inc collectively complainants filed complaint united states international trade commission itc daewoong pharmaceuticals co ltd daewoong co ltd evolus inc collectively respondents requesting itc commence investigation regarding importation united states respondents ' botulinum neurotoxin products including jeuveau complainants assert developed using medytox 's trade secrets complainants seek permanent exclusion cease desist orders covering respondents ' products including jeuveau july administrative law judge issued initial ruling favor allergan medytox december full commission affirmed part reversed part initial ruling august btl industries inc btl filed itc action allergan usa inc allergan limited allergan inc zeltiq aesthetics inc zeltiq ireland unlimited company zimmer medizinsysteme gmbh patent infringement alleging cooltone coolsculpting devices infringe patents seeking exclusion order preventing importation devices components used make use devices note segment geographic area information abbvie operates single global business segment dedicated research development manufacturing commercialization sale innovative medicines therapies operating structure enables chief executive officer chief operating decision maker codm allocate resources assess business performance global basis order achieve established longterm strategic goals consistent structure global research development supply chain organization responsible discovery manufacturing supply products commercial efforts coordinate marketing sales distribution products organized geographic region therapeutic area activities supported global corporate administrative staff determination single business segment consistent consolidated financial information regularly reviewed codm purposes assessing performance allocating resources planning forecasting future periods substantially abbvie 's net revenues united states three wholesalers outside united states products sold primarily health care providers distributors depending market served following tables detail abbvie 's worldwide net revenues years ended december millions immunology humira united states international total skyrizi united states international total rinvoq united states international total hematologic oncology imbruvica united states collaboration revenues total venclexta united states international total aesthetics botox cosmetic united states international total juvederm collection united states international total aesthetics united states international total neuroscience botox therapeutic united states international total vraylar united states duodopa united states international total ubrelvy united states neuroscience united states international total form kyears ended december millions eye care lumiganganfort united states international total alphagancombigan united states international total restasis united states international total eye care united states international total women 's health lo loestrin united states international total orilissaoriahnn united states international total women 's health united states international total key products mavyret united states international total creon united states lupron united states international total linzessconstella united states international total synthroid united states total net revenues net revenues include allergan product revenues date acquisition may december net revenues external customers geographic area based product shipment destination follows years ended december millions united states japan canada germany france australia united kingdom china spain brazil italy countries total net revenues longlived assets primarily net property equipment geographic area follows december millions united states puerto rico europe total longlived assets note fourth quarter financial results unaudited quarter ended december millions except per share data net revenues gross margin net earnings attributable abbvie inca basic earnings per share attributable abbvie inc diluted earnings per share attributable abbvie inc cash dividends declared per common share fourth quarter results included aftertax charges billion related change fair value contingent consideration liabilities partially offset aftertax benefit billion due impacts related tax law changes form kreport independent registered public accounting firm stockholders board directors abbvie inc opinion financial statements audited accompanying consolidated balance sheets abbvie inc subsidiaries company december related consolidated statements earnings comprehensive income equity cash flows three years period ended december related notes collectively referred financial statements opinion financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states pcaob company 's internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon basis opinion financial statements responsibility company 's management responsibility express opinion company 's financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion critical audit matters critical audit matters communicated matters arising current period audit financial statements communicated required communicated audit committee relate accounts disclosures material financial statements involved especially challenging subjective complex judgments communication critical audit matters alter way opinion financial statements taken whole communicating critical audit matters providing separate opinions critical audit matters accounts disclosures relate sales rebate accruals medicaid medicare managed care programs description matter discussed note consolidated financial statements caption revenue recognition company established provisions sales rebates period related product sold december company million sales rebate accruals large portion rebates provided pharmacy benefit managers state government medicaid programs insurance companies administer medicare drug plans private entities medicaid medicare managed care programs order establish sales rebate accruals company estimated rebates based upon identification products subject rebate applicable price rebate terms estimated lag time sale payment rebate auditing medicaid medicare managed care sales rebate accruals complex required significant auditor judgment accruals consider multiple subjective complex estimates assumptions estimates assumptions included estimated inventory distribution channel impacts lag time sale customer payment rebate final payer related product sales impacts applicable price rebate terms deriving estimates assumptions company used internal external sources information estimate product distribution channels payer mix prescription volumes historical experience management supplemented historical data analysis qualitative adjustments based upon changes rebate trends rebate programs contract terms legislative changes significant events indicate change reserve appropriate addressed obtained understanding evaluated design tested operating effectiveness controls matter audit companys sales rebate accruals medicaid medicare managed care programs included testing controls managements review significant assumptions inputs used estimation medicaid medicare managed care rebates among others including significant assumptions discussed testing inclusive managements controls evaluate accuracy reserve judgments actual rebates paid rebate validation processing controls ensure data used evaluate support significant assumptions complete accurate applicable verified external data sources test sales rebate accruals medicaid medicare managed care programs audit procedures included among others understanding evaluating significant assumptions underlying data used managements calculations testing significant assumptions included corroboration external data sources evaluated reasonableness assumptions considering industry economic trends product profiles regulatory factors assessed historical accuracy managements estimates comparing actual activity previous estimates performed analytical procedures based internal external data sources evaluate completeness reserves medicaid involved specialist understanding statutory reimbursement requirements assess consistency companys calculation methodologies applicable government regulations policy valuation contingent consideration description matter discussed note consolidated financial statements caption business combinations note caption financial instruments fair value measures company recognized contingent consideration liabilities estimated fair value acquisition date connection applying acquisition method accounting business combinations subsequent changes fair value contingent consideration liabilities recorded within consolidated statement earnings period change december company million contingent consideration liabilities represented level fair value measurement fair value hierarchy due significant unobservable inputs used determining fair value use management judgment assumptions market participants would use pricing liabilities auditing valuation contingent consideration liabilities complex required significant auditor judgment due use monte carlo simulation model high degree subjectivity evaluating certain assumptions required estimate fair value contingent royalty payments particular fair value measurement sensitive significant assumptions underlying estimated amount future sales acquired products management utilized expertise within industry including commercial dynamics trends utilization well knowledge clinical development regulatory approval processes determine certain assumptions form khow addressed obtained understanding evaluated design tested operating effectiveness controls matter audit companys contingent consideration liabilities process including among others managements process establish significant assumptions measure liability included testing controls managements review significant assumptions inputs used determination fair value testing inclusive key management review controls monitor evaluate clinical development acquired products estimated future sales controls ensure data used evaluate support significant assumptions complete accurate applicable verified external data sources test estimated fair value contingent consideration liabilities audit procedures included among others inspecting terms executed agreement assessing monte carlo simulation model used testing key contractual inputs significant assumptions discussed evaluated assumptions judgments considering observable industry economic trends standards external data sources regulatory factors estimated amounts future sales evaluated reasonableness relation internal external analyses clinical development progress timelines probability success benchmarks regulatory notices procedures included evaluating data sources used management determining assumptions necessary included evaluation available information either corroborated contradicted managements conclusions involved valuation specialist assess companys monte carlo simulation model perform corroborative fair value calculations accounting allergan plc acquisition valuation intangible assets description matter discussed note consolidated financial statements caption licensing acquisitions arrangements company completed acquisition allergan plc allergan may approximately million company measured assets acquired liabilities assumed fair value resulted recognition million intangible assets comprised million developed product rights million inprocess research development iprd auditing valuation intangible assets complex required significant auditor judgment due high degree subjectivity evaluating certain assumptions required estimate fair value identified intangible assets particular fair value measurement sensitive managements forecasts net revenues including growth rates used estimate future net cash flows acquired aesthetics recently launched products addressed obtained understanding evaluated design tested operating effectiveness controls matter audit companys accounting acquisitions including among others managements process establish significant assumptions used determining fair values intangible assets included testing controls managements review significant assumptions inputs used determination estimated future net revenues determination future net cash flows estimated growth rates review valuation model test estimated fair value intangible assets audit procedures included among others inspecting terms executed agreement evaluating valuation methods used testing significant assumptions discussed evaluated assumptions judgments considering observable industry economic trends standards external data sources historical product trends including comparable products extent applicable estimated future net revenues evaluated reasonableness internal external analyses including analyst expectations industry trends market trends procedures included evaluating data sources used management determining assumptions necessary included evaluation available information either corroborated contradicted managements conclusions involved valuation specialist assess valuation model perform corroborative fair value calculations accounting allergan plc acquisition unrecognized tax benefits description matter discussed note caption income taxes part acquisition allergan plc company recorded million unrecognized tax benefits resulting uncertain tax positions company applied judgment evaluating completeness unrecognized tax benefits assumed acquisition date significant judgments inherent companys evaluation assumed uncertain tax positions included whether tax positions technical merits morelikelythannot sustained including consideration applicable tax statutes related interpretations precedents expected outcome proceedings negotiations taxing legal authorities auditing companys analysis accounting uncertain tax positions complex due interpretation tax laws legal rulings multiple tax paying jurisdictions required significant judgment determining whether assumed tax positions technical merits morelikelythannot sustained particular assumed unrecognized tax benefit involved unique facts circumstances multiple potential outcomes evaluated many uncertainties around initial recognition including regulatory changes litigation examination activity management utilized outside tax legal counsel appropriate evaluation addressed obtained understanding evaluated design tested operating effectiveness controls matter audit companys accounting acquisitions including among others managements process evaluate completeness estimation unrecognized tax benefits included testing controls managements determination whether assumed tax positions technical merits morelikelythannot sustained recognizing estimated amount qualified tax benefit also obtained understanding evaluated design tested operating effectiveness controls ensure data used evaluate support significant fair value assumptions unrecognized tax benefits complete accurate applicable verified external data sources test completeness recognition unrecognized tax benefits audit procedures included among others testing managements process estimating unrecognized tax benefits testing managements process included assessing managements interpretation unique facts circumstances related tax laws legal rulings tax paying jurisdiction examining whether technical merits tax position morelikelythannot sustained evaluating recognition amount qualified tax benefit professionals specialized skill knowledge used assist evaluation completeness recognition companys unrecognized tax benefits including consideration applicable tax statutes related interpretations precedents ernst young llp served companys auditor since chicago illinois february form kitem changes disagreements accountants accounting financial disclosure none item controls procedures disclosure controls procedures internal control financial reporting evaluation disclosure controls procedures chief executive officer richard gonzalez chief financial officer robert michael evaluated effectiveness abbvie 's disclosure controls procedures end period covered report concluded abbvie 's disclosure controls procedures effective ensure information abbvie required disclose reports files submits securities exchange commission securities exchange act recorded processed summarized reported within time periods specified commission 's rules forms ensure information required disclosed abbvie reports files submits securities exchange act accumulated communicated abbvie 's management including principal executive officer principal financial officer appropriate allow timely decisions regarding required disclosure changes internal control financial reporting changes abbvie 's internal control financial reporting defined rule f securities exchange act materially affected reasonably likely materially affect abbvie 's internal control financial reporting quarter ended december inherent limitations effectiveness controls abbvie 's management including chief executive officer chief financial officer expect abbvie 's disclosure controls internal control financial reporting prevent detect errors fraud control system matter well designed operated provide reasonable absolute assurance control system 's objectives met design control system must reflect fact resource constraints benefits controls must considered relative costs inherent limitations control systems evaluation controls provide absolute assurance misstatements due error fraud occur control issues instances fraud detected inherent limitations include realities judgments decisionmaking faulty breakdowns occur simple error mistake controls also circumvented individual acts persons collusion two people management override controls design system controls based part certain assumptions likelihood future events assurance design succeed achieving stated goals potential future conditions projections evaluation controls effectiveness future periods subject risks time controls may become inadequate changes conditions deterioration degree compliance policies procedures management 's annual report internal control financial reporting management abbvie responsible establishing maintaining adequate internal control financial reporting term defined rule af securities exchange act abbvie 's internal control financial reporting designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles united states however internal control systems matter well designed inherent limitations therefore even systems determined effective provide reasonable assurance respect financial statement preparation reporting management assessed effectiveness abbvie 's internal control financial reporting december making assessment management used criteria set forth committee sponsoring organizations treadway commission coso internal controlintegrated framework framework based assessment management concluded abbvie maintained effective internal control financial reporting december based coso criteria effectiveness abbvie 's internal control financial reporting december audited ernst young llp independent registered public accounting firm stated attestation report expresses unqualified opinion effectiveness abbvie 's internal control financial reporting december report independent registered public accounting firm report abbvie 's independent registered public accounting firm related assessment effectiveness internal control financial reporting included report independent registered public accounting firm stockholders board directors abbvie inc opinion internal control financial reporting audited abbvie inc subsidiaries ' internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria opinion abbvie inc subsidiaries company maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states pcaob consolidated balance sheets abbvie inc subsidiaries december related consolidated statements earnings comprehensive income equity cash flows three years period ended december related notes report dated february expressed unqualified opinion thereon basis opinion company 's management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying management 's annual report internal control financial reporting responsibility express opinion company 's internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting company 's internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles company 's internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition company 's assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate ernst young llp chicago illinois february form kitem b information none part iii item directors executive officers corporate governance incorporated herein reference information concerning director nominees board directors committeescommittees board directors procedure recommendation nomination directors transaction business annual meeting included abbvie inc proxy statement definitive proxy statement filed march also incorporated herein reference text found caption information executive officers abbvie 's code business conduct requires business activities conducted compliance applicable laws regulations ethical principles values directors officers employees abbvie required read understand abide requirements code business conduct applicable abbvie 's code business conduct available corporate governance section abbvie 's investor relations website wwwabbvieinvestorcom waiver code business conduct directors executive officers may made abbvie 's audit committee abbvie disclose amendment waiver provision code conduct principal executive officer principal financial officer principal accounting officer controller persons performing similar functions website within four business days following date amendment waiver addition abbvie disclose waiver code business conduct executive officers directors website abbvie chief ethics compliance officer reports vice chairman external affairs chief legal officer public policy committee chief ethics compliance officer responsible overseeing administering monitoring abbvie 's compliance program item executive compensation material included abbvie inc proxy statement headings director compensation executive compensation compensation committee report incorporated herein reference definitive proxy statement filed march form kitem security ownership certain beneficial owners management related stockholder matters equity compensation plan information following table presents information december abbvie 's equity compensation plans abbvie common stock authorized issuance number c securities number securities issued upon b remaining available exercise weighted future issuance equity outstanding average exercise price compensation plans options outstanding options excluding securities warrants warrants reflected plan category rights rights column equity compensation plans approved security holders equity compensation plans approved security holders total includes shares issuable abbvie 's incentive stock program pursuant awards granted abbott adjusted abbvie awards connection abbvie 's separation abbott weightedaverage exercise price include outstanding restricted stock units restricted stock awards performance shares exercise price excludes shares issuable upon exercise stock options pursuant rights granted stemcentrx equity incentive plan assumed abbvie upon consummation acquisition stemcentrx inc december options remained outstanding plan options weightedaverage exercise price awards granted plan b information concerning security ownership incorporated herein reference material heading securities ownershipsecurities ownership executive officers directors abbvie inc proxy statement definitive proxy statement filed march item certain relationships related transactions director independence material included abbvie inc proxy statement headings board directors committees corporate governance materials procedures approval related person transactions incorporated herein reference definitive proxy statement filed march item principal accounting fees services material included abbvie inc proxy statement headings audit fees nonaudit fees policy audit committee preapproval audit permissible nonaudit services independent registered public accounting firm incorporated herein reference definitive proxy statement filed march part iv item